



Funded by the European Union

EUonQoL

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Deliverable number: 5.2

Deliverable title: Report on cultural/social/psychological factors

Deliverable type	Document, report	
Deliverable responsible partner	IEO and SporeData	
Authors	IEO: Diana Sala, Chiara Marzorati, Viktorya	
	Voskanyan, Roberto Grasso, Gabriella Pravettoni	
	Co-researchers: Carina Dantas, Laura Pinnavaia:	
	SporeData: Ricardo Pietrobon, Aline Machiavelli,	
	Mirtha Valencia, Rafael Woloski	
Contractual date of delivery	Month: April 2024 Month 16	
Actual date of delivery	Month: April 2024 Month 16	
Dissemination level	Public	
Status of deliverable	Final version	

Grant Agreement information table	
Grant Agreement number	101096362
Project acronym	EUonQoL
Project title	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
Start date	1 January 2023
Duration	48 months

"This project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No 101096362".

EUonQoL





Funded by the European Union

Preface

This report is written as a product of the project "Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe (EUonQoL)". This project is funded by the European Union.

The authors from IEO team and Sporedata team would like to thank the EUonQoL Executive Committee for providing us with input on the tasks, roles, and responsibilities that co-researchers have been involved in.

Furthermore, both teams would like to thank co-researchers (Carina Dantas and Laura Pinnavaia) for their involvement and input addressed during the entire process to reach the aims of WP5 Tasks.

The authors would like finally to thank NIVEL (Netherlands Institute for Health Services Research) for the collaboration within Work Package 5 of the EUonQoL project and along the collaboration with corresearchers.

Diana Sala (IEO)

Chiara Marzorati (IEO)

Viktorya Voskanyan (IEO)

Roberto Grasso (IEO)

Gabriella Pravettoni (IEO)

Ricardo Pietrobon (SporeData)

Aline Machiavelli (SporeData)

Mirtha Valencia (SporeData)

Rafael Woloski (SporeData)





Funded by the European Union

Summary

Ρı	eface		2
1.	Introdu	uction	5
	1.1. Th	ne EUonQoL project	5
	1.1.1.	Population: Active treatment, Survivors, Palliative Care	6
	1.2. Ai	m of the Report	7
2.	URs o	f quantitative studies	8
	2.1. Li	terature research	8
	2.2. Se	election process and methodology	8
	2.2.1.	Inclusion and exclusion criteria	8
	2.2.2.	Literature search and data selection	9
	2.2.3.	Data Synthesis	9
	2.2.4.	Quality assessment	9
	2.2.5.	Results	10
3.	Meta-r	neta-analysis of qualitative studies	13
	3.1. Li	terature research	13
	3.2. M	ethodology and selection process	14
	3.2.1.	Inclusion and exclusion criteria	14
	3.2.2.	Literature search and data selection	14
	3.2.3.	Data synthesis	14
	3.2.4.	Quality assessment	15
4.	Sentim	nent analysis	23
	4.1. M	ethodology of NLP process and text analysis	24
	4.1.2.	Analysis of Tweet Content	25
	4.1.3.	Challenges in Data Collection	26
5.	Conclu	usions	27
6.	Appen	dix	29
	6.1. Li	st of search strings	29
	6.1.1.	Search strings for Scopus	29
	6.1.2.	Search strings for Embase	32

	EUonQoL	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	* * * * * Funded by the European Union
6.1.3.	Search strings for Pu	bMed	
6.1.4.	Search strings used f	or PsycInfo	
6.2. Ta	ble Active treatment		
6.2.1.	Table 2 - Characteris	tics of the included studies	
6.2.2. Table 3 - Characteristics of the included studies			
6.3. Ta	ble Survivors		
6.3.1. Table 4 - Characteristics of the included studies			
6.3.2.	6.3.2. Table 5 - Characteristics of the included studies		
6.4. Ta	ble End of Life and Pall	iative Care	
6.4.1.	Table 6 - Characteris	tics of the included studies	
6.4.2.	6.4.2. Table 7 - Characteristics of the included studies		





Funded by the European Union

1. Introduction

The first part of the present report will provide an overview of the EUonQoL project within which this report is produced. Additionally, it will introduce and outline the objectives and contents of the present report. Subsequently, the next paragraphs will present and delineate methodologies followed to reach the aim of task 5.1 and the material used to keep track of it. Conclusions are presented in the final part of the report.

This WP is part of an EU funded project entitled "EUonQoL-Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe" (grant agreement n° 101096362).

The overall project aims to develop, pilot and validate the European Oncology Quality of Life toolkit (EUonQoL-Kit), a patient co-researcher driven, unified system for the assessment of quality of life (QoL) based on the evaluations and preferences of cancer patients (ongoing treatment, palliative care) and survivors. The EUonQoL-Kit has been developed from the patient perspective, administered digitally, and will be available in all 27 European Union (EU) languages and in the languages of the associated countries.

1.1.The EUonQoL project

Cancer is the second cause of death and the first cause of suffering for patients and caregivers in Europe, as well as it has an enormous financial impact on health services and individuals. There were 2.7 million new cases of cancer and 1.3 million deaths in 2020, which is expected to increase with about 25% by 2035. Additionally, there is an unacceptable variability in terms of access to innovation, quality of care, and outcomes (including QoL), within and between countries in Europe. QoL can be interpreted as satisfaction and happiness measured, as the achievement of aspirations and/or the realization of individual expectations. The burden of cancer and cancer treatment on QoL is well-recognized. Nonetheless, the implementation of QoL assessment in routine oncology practice is not yet part of the standard of care. In the same way, health care systems and cancer control programs do not take into consideration QoL measures when developing clinical, societal, and healthcare policymaking systems.

Emerging needs related to new cancer treatments along with societal developments require a revision of traditional QoL assessment tools, most of which have been developed a few decades ago and are not available in all official and non-official European languages.

Available questionnaires are often "static", thus presenting the same set of questions/items to all patients, without any difference. A recent innovation in the assessment of HRQoL (Health-Related Quality of Life) in cancer care is the development of the Computer-Adaptive Testing (CAT). CAT allows a more precise assessment of HRQoL, with systems presenting subsequent questions based on answers of the previous ones, ultimately adapting the questions to the health state of the individual patient. In addition, most existing HRQoL tools were developed to be filled out with paper and pencil. CAT tools will in turn allow for more dynamic instruments, suitable for a personalized patient's experience of data collection. The overall project process wants to ensure that the EUonQoL-Kit and its future development would be a unified, standard European QoL assessment system. For the aforementioned reasons, significant focus was directed towards the translation process, in order to ensure a consistently high standard of translated materials and to cover both linguistical and cultural diversity across Europe.

In Table 1 all WPs involved in the project are presented. EUonQoL





Funded by the European Union

Work Package	WP Title
WP1	Ethics
WP2	Involvement of stakeholders and patients
WP3	Review of existing HRQoL databases, measures and item libraries
WP4	Development of the EUonQoL-Kit
WP5	Cross-cultural determinants of the QoL and linguistic and cultural adaptation of EUonQoL-Kit
WP6	Digital tools for data collection
WP7	EUonQol-Kit Pilot Survey
WP8	Implementation
WP9	Dissemination
WP10	Project Management/Coordination

 Table 1 Work packages of the EUonQoL EU project

To gain a better understanding of the process utilized in the EUonQoL project, refer to Figure 1, which depicts the flow diagram illustrating the involved Work Packages and their connections.




Figure 1 Flow diagram of project

1.1.1. Population: Active treatment, Survivors, Palliative Care

The aim of the EUonQoL-Kit is to reflect the spectrum of patients diagnosed with cancer. The questionnaires will be administered and validated in three different cancer groups: active treatment, survivors, and palliative care. The definitions outlined within the project might not be exhaustive of the whole cancer patient population, but they are essential to validate the tool and to be able to distinguish three different patient groups with relative precision. As agreed with the EUonQoL Consortium, the target population groups are defined throughout all stages of this study as:

EUonQoL





Funded by the European Union

Group A. Active Treatment:

i. curative treatment - undergoing or recently completed curative treatment for early-stage cancers.

Examples: - Early stage 1-2 breast cancer during or up to 3 months following radiotherapy, surgery or systemic treatments.

ii. non-curative treatment for advanced/metastatic cancers, including disease controlling/life prolonging tumour-directed treatment (e.g. patients with metastatic disease receiving chemotherapy, immunotherapy or targeted agents).

Examples: - Metastatic breast cancer on 1st line palliative chemotherapy; - Lung cancer on immunotherapy.

Group B. Survivors:

i. At least one year off active treatment (but can be on long-term adjuvant hormonotherapy) and being disease-free without evidence of active cancer.

Examples: - ER/PR+ breast cancer treated with surgery, adjuvant radiotherapy and on 10 years of hormonal treatment.

Group C. Palliative Care: Patients with advanced cancers who meet at least one of the following criteria:

i. Patients with projected prognosis <=70 or ECOG <=2.

ii. Patients referred to a specialist palliative care team for symptom control.

iii. Patients may be receiving non-curative treatment purely for symptom control (including palliative radiotherapy and/or systemic treatment).

Examples: - Patients with castrate-resistant prostate cancer, progressed through systemic treatment options referred for radiotherapy for bone pain; - Metastatic breast cancer patient on 5th line systemic treatment.

1.2.Aim of the Report

This report refers to Task 5.1 conducted within the Work Package 5.

The aim of T5.1 is to define a set of key clinical, cultural, sociodemographic and psychosocial factors associated with QoL.

The obtained results would enrich the findings reported in WP3 and WP4 and highlight potential differences with the domains included in the EUonQoL-Kit; they would also be used to define factors to be collected in the CRF (Case Report Form) developed within the WP7 Pilot Survey.

To reach this aim, WP5 performed three quantitative studies (three Umbrella Reviews), a qualitative study (meta-meta-analysis) and a sentiment analysis (Natural Language Process, NLP) that will be separately described in the following paragraphs.

Finally, to ensure that all the aspects were correctly addressed, all data collected were discussed among all the partners and co-researchers involved in this WP.

At the end of the process, a group of experts, including co-researchers, reviewed the obtained results, to identify any discrepancies and reach consensus.

EUonQoL





Funded by the European Union

2. URs of quantitative studies

The European Institute of Oncology IRCCS (Leader of the WP5) performed three Umbrella Reviews (URs) to identify quantitative research studies investigating psychosocial factors associated with QoL in patients with active treatments, in palliative care, and survivors, respectively.

Due to the great number of systematic reviews already available on this topic, the IEO team decided to conduct an UR, with the aim of summarizing the results of multiple systematic reviews. Indeed, the UR is considered one of the highest levels of evidence currently available and is aimed at conducting a narrative compilation of evidence from multiple systematic reviews and meta-analysis into one document with text, tables, and graphics. It is designed to provide a summary of existing research syntheses related to a given topic or question.

All the URs were conducted following the guidelines from Joanna Briggs Institute (JBI) (Aromataris et al., 2015) and registered in the International Prospective Register of Systematic Reviews with the following PROSPERO protocol numbers:

- CRD42023413899: UR on patients undergoing active treatments;
- CRD42023415288: UR on cancer survivors;
- CRD42023413281: UR on patients in palliative care.

2.1.Literature research

A search strategy was built and adapted for each UR depending on patients' group. A research librarian was involved and created different search strings for the following four electronic scientific databases: PubMed, Embase, Scopus and PsycInfo. These search strings were optimized with a combination of several search terms divided into the following topics: Cancer, Quality of Life, Factors, Psychosocial, Impact, and adapted for each patients group. Specific search strings developed for each database are presented in Appendix.

2.2.Selection process and methodology

2.2.1. Inclusion and exclusion criteria

For the present URs clear exclusion and inclusion criteria were established to avoid biases that may impact the quality of the research. Hence, the research was limited to (a) systematic reviews, (b) without geographical restrictions, (c) conducted from 1st January 2012 to January 2023 (the research was limited to this year because the field of cancer care is rapidly changing), (d) including adult cancer patients (>18 years), (e) active treatment, or survivors or in palliative care and (f) investigating the relationship between QoL and psychosocial factors. These eligibility criteria were established according to the research question (PICO questions; P: adult cancer patients; I: not applicable; C: not applicable; O: factors affecting QoL).

The exclusion criteria for the present UR included (a) non-psychosocial factors associated with QoL (e.g. economic, cultural, pharmacological outcomes), (b) non-adult or non-cancer patients (e.g., adolescents, population with other diseases aside from cancer, caregivers, children, etc).





Funded by the European Union

2.2.2. Literature search and data selection

Starting from this search strategy, two researchers started the preliminary screening independently (reading titles and abstracts) using Rayyan (Ouzzani et al., 2016) to import results. Rayyan is an online Software, which allows the use of the "blinded" mode for reviewing papers. Duplicates from different electronic databases were removed automatically by Rayyan. Any disagreements concerning the eligibility of studies were resolved by the third researcher through group discussion and full-text review.

All reviews potentially eligible for inclusion were retrieved for full-text screening based on the inclusion and exclusion criteria. Any doubts regarding final inclusion were solved through consensus. Additionally, the reference lists of all included articles were screened to identify other relevant articles not detected in the automated search. Grey literature was not taken into consideration.

Subsequently, the research team organized three Excel© worksheets (one for each population group) containing included articles with the following categories: publication data (title, authors, year), study origin, study characteristics (number of studies included in each review, study design, year of publication of included articles, country of origin), aim of each review, participant details (total number, sociodemographic characteristics if mentioned), type of cancer diagnosis, and factors (psychological and social). The authors also gathered clinical factors identified in studies exploring psychosocial factors. For more details about the Excel© worksheet, see Appendix.

2.2.3. Data Synthesis

The selected reviews were reported using the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Page et al., 2021); Once the consensus of the reviewers was reached, these identified data were incorporated into the Excel© table.

2.2.4. Quality assessment

Two investigators independently evaluated the methodological quality of the included Systematic Reviews and Meta-analyses using the Assessment of Multiple Systematic Reviews 2 (AMSTAR2) (Shea et al., 2017)rating scale. Any discrepancies in ratings were resolved through discussion. This assessment tool consists of 16 items designed to assess the quality and bias of the selected studies. Each article received a score based on the number of positive, partially positive, and negative responses. A higher rate of positive responses indicated a lower risk of bias.

Researchers adhered to the AMSTAR 2 rating guidelines, but modifications were made for item 1 ("Did the research questions and inclusion criteria for the review include the components of PICO?"). For this item, the scoring approach was adjusted as follows: responses were categorized as "Yes," "Partially yes," or "Not." A rating of "Yes" was assigned if the included Systematic Review (SR) had a clearly defined research question and explicitly described all components of PICO somewhere in the SR's report. The rating "Partially yes" was used when the PICO questions were only partially described in the SR. For example, if the SR reported only the study population and outcome, the authors assigned a "Partially yes" rating instead of "Not".

The main questions where most of the systematic reviews included in the URs failed regarded 1) the registration of the protocol, 2) the explanation of the selection of the study design, 3) the provision of the list of the excluded studies, and 4) the report on the sources of income of the included studies. EUonQoL Pag. 9 | 100





Funded by the European Union

2.2.5. Results

The search in 4 electronic databases identified 2872 potentially relevant references for patients undergoing treatment, 506 references for survivors, and 256 for patients in palliative care, respectively. After the removal of the duplicates, 1952 SRs remained for title and abstract screening for patients undergoing treatment, 315 reviews for survivors, and 176 reviews for patients in palliative care. After the initial screening, 53 reviews were retrieved for full-text screening for patients undergoing treatment, 29 reviews for survivors, and 6 reviews for patients in palliative care. Full-text screening identified 18 SRs that met the inclusion criteria for patients undergoing treatment, 13 SRs for survivors, and 3 reviews for patients in palliative care.

Results of the **UR for patients ongoing treatment** show that QoL in this population group is associated with the following psychosocial factors: depression, coping/coping strategies (i.e. problemsolving and positive thinking), social support/functioning/interactions, anxiety, distress, faith/religiosity, optimism, resilience, unmet needs, body image, emotional focus/functioning, neuroticism, self-efficacy, spiritual well-being, avoidance, boredom, confidence about remaining cancer-free, empowerment, external/internal locus control, extraversion, family harmony status, fear of cancer recurrence, harm avoidance, helplessness, hope, illness perception, impaired mental health, mental fatigue, mental health, openness, personal control over the patients' own disease, personality type D, positive illness perception, positive mood, post-traumatic growth, post-traumatic stress disorder, psychological symptoms, psychological well-being, reduced motivation, sadness, satisfaction with esthetic outcome, self-regulation, sense of coherence, somatization, tolerant personality type, trait anxiety, healthier behavior, exercise, role limitations, and sense of self-efficacy (for a better understanding of the aforementioned results please refer to Figure 2). This study also identifies significant clinical factors documented in the SRs included. The following clinical factors result negatively associated with QoL in this patients' group: chemotherapy, tumor stage, symptoms, and presence of recurrence. Furthermore, some contradictory results are associated with the following clinical factors: comorbidities, epilepsy, hormone therapy, radiotherapy, and time since diagnosis; indeed, some reviews show a positive association with QoL and others a negative one. Interestingly, one study shows a positive association between immune therapy and QoL.





Funded by the European Union




Figure 2 Psychosocial factors associated with QoL in patients in active treatment

For **the survivors group**, the factors associated with QoL found in the UR are the following: social support/interactions, coping/coping strategies, depression, stress/psychological distress, emotions/ emotional well-being/emotional abilities/emotional growth, anxiety, fear of cancer recurrence, post-traumatic growth, body image distress/body image concerns, sense of coherence, neuroticism, spiritual growth/faith, meaning/peace, post-traumatic growth, post-traumatic stress disorder, resilience, well-being at the time of diagnosis, body image distress, optimism, negative cancer-threat appraisal, less benefit finding, denial, hostility, pessimism, hope, impaired sexual life, cancer-threat appraisal, repression defense, post-traumatic stress disorder (Please see Figure 3). While investigating psychosocial factors associated with QoL in cancer survivors, this UR also extracts some major clinical factors reported in the systematic reviews. Specifically, our findings demonstrate that comorbidities, adverse symptomology, cancer and treatment-related symptoms have been negatively associated with QoL. Contradictory results are highlighted regarding the association between QoL and tumor grade, tumor location, adjuvant therapy, and time after treatment. In addition to the findings mentioned above, there are also other clinical factors negatively impacting QoL: epilepsy/seizure burden, worse Tumor-Nodes-Metastasis (TNM), more extensive surgery, tumor recurrence, fatigue, and short-term surgical complications.




Figure 3 Psychosocial factors associated with QoL in cancer survivors

Results for **patients in palliative care** highlight the following psychosocial factors associated with QoL: depression and anxiety, spirituality/religiosity, diagnosis awareness, depression, feeling of coherence, intrusive thoughts, awareness of terminal disease, spirituality (faith and meaning/peace), and family function/support (Please see Figure 4). Two SRs also investigated the association between clinical variables on QoL. Specifically, undergoing medical treatment or symptom management strategies positively impact on QoL, while pain intensity, fatigue, effects of targeted treatments and severity of the disease negatively affect QoL.

Wellibeing

SUPP




Figure 4 Psychosocial factors associated with QoL in patients in palliative care

3. Meta-meta-analysis of qualitative studies

The aim of the present review, conducted by Sporedata team, was to analyze the evidence of sociodemographic, cultural, clinical, and psychosocial variables that may impact the quality of life (QoL) in cancer patients and survivors. A Systematic Review (SR) of qualitative studies assessing cancer patients' QoL was performed, considering risk perception, lifestyle, environment, and early-life factors. Additionally, the studies were geocoded to verify any differences between Western and Eastern Europe. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Stewart et al., 2015) have been followed to ensure accurate and transparent article selection.

3.1.Literature research

To gather relevant data for a comprehensive SR, a rigorous and comprehensive search was conducted for studies focusing on QoL in cancer patients published between 2013 and 2022. Four major scientific electronic databases (PubMed, Scopus, EMBASE, and OVID) served as the basis for the search strategy. To streamline the selection process, specific search terms were used, tailored for systematic reviews or meta-reviews of qualitative studies evaluating the QoL in cancer patients. This strategy aimed to retrieve the most relevant studies in the field. The search strategy was carefully constructed as follows: (cancer OR tumor OR tumour OR neoplas* OR oncolog) AND ("meta-analysis" OR "systematic review") AND ("quality of life" OR "QOL") AND (experience OR interview* OR "emerging themes") AND ("qualitative studies"). This methodological approach facilitated exploring relevant scientific articles while focusing on our research objective.

EUonQoL





Funded by the European Union

3.2.Methodology and selection process

3.2.1. Inclusion and exclusion criteria

A strict set of criteria in the selection process was applied. The search strategy was limited to original researches published in five major European languages: English, Spanish, Italian, Portuguese, and French. Conference abstracts, editorials, and review articles were excluded to ensure research rigour and validity, as these publications may lack necessary detail or peer review. The inclusion criteria were limited to SRs or meta-reviews that examined the QoL in cancer patients using qualitative research methods. The aim was to gain a comprehensive understanding of the lived experiences of these individuals by analyzing the themes that emerged from the interviews. Interventional and cross-sectional studies were excluded from the selection process to maintain a robust methodology and clear focus. Through meticulously adhering to these selection criteria, the aim was to distil a rich and nuanced understanding of the QoL in cancer patients from a qualitative perspective.

3.2.2. Literature search and data selection

Data from qualitative studies were gathered in the selected SRs and meta-reviews. Qualitative studies that were published before 2013 and those that did not focus on cancer patients were excluded. For each qualitative study, the following labels were recorded: title, year of publication, themes that emerged from the interviews, patient group (active treatment, survivors, and end-of-life/palliative), and location data (geocoding). In cases where the articles did not include location information, the authors were contacted to request the countries from which the patients were recruited. It is important to mention that the scope of the analysis extended beyond studies focusing on a single patient group. Some research encompassed multiple groups, examining the interplay of psychosocial, risk perception, lifestyle, and environmental factors across different stages of the patient experience. Specifically, several studies provided insights into ongoing treatment and cancer survivorship, while others bridged the experiences of patients undergoing ongoing treatment with those in end-of-life care. To assess the risk of bias and study quality of the papers, the "Quality in Qualitative Evaluation: a Framework for Assessing Research Evidence (The Spencer Framework) (Spencer et al., 2004) was followed. This framework was chosen for its holistic evaluation approach, which was crucial for ensuring the findings' credibility and relevance.

3.2.3. Data synthesis

Different factors related to cancer patients' QoL outcomes were analyzed, with a focus on emerging themes and their context within qualitative studies. This analysis examined the psychosocial dimension derived from previous umbrella reviews of quantitative studies. These studies assessed psychosocial factors in three subgroups of cancer patients, which included those receiving ongoing treatment, those in end-of-life or palliative care, and cancer survivors. The studies were submitted to PROSPERO under the registration numbers CRD42023413899, CRD42023413281, and CRD42023415288. This classification provided a solid foundation of psychosocial factors that guided the qualitative data analysis.

In addition to the psychosocial factors, other factors already published in the literature were examined, such as risk perception, lifestyle, environmental, and early life factors (Cárceles-Álvarez et al., 2020; Murphy et al., 2019; Parkin et al., 2011; Tilburt JC, et al., 2012; van Roekel et al., 2014). A table





listing each study was prepared. To facilitate the interpretation of the contextual themes, some statements were extracted from the original text and added to a column in this table for reference. Then, the respective factors were placed in the columns next to them. Utilizing the sets of factors related to the QoL as parameters ensured a comprehensive and meaningful analysis of the emerging themes from the qualitative studies.

3.2.4. Quality assessment

Exploratory analyses were used to gain comprehensive insights into the data. The objective was to explore the relationship between cancer patients' QoL and various contributing factors, including psychosocial, risk perception, lifestyle, environmental, and early life. An evaluation of how these relationships vary among different subgroups of cancer patients was also conducted. Bar plots were created to visually represent the distribution of QoL across three different subgroups of cancer patients.

In addition to analyzing the factors across patient groups, visual representations were also constructed to showcase the geographical distribution of the studies included in the analysis. A world map plot provided a global overview, indicating the number of studies per country, with varying shades of color denoting the count. A more detailed plot focused on the European Union, highlighting the studies per country within this region. Further, bar plots were created to compare the distribution of the studied factors between Eastern and Western European countries, illustrating the number of factors stratified by region and patient group.

3.2.5. Results

Twenty-two studies focused on examining cancer patients' QoL were identified. These studies were meta-analyses and systematic reviews that used qualitative research methods.

The search covered the PubMed, EMBASE, OVID, and Scopus databases, resulting in 265 systematic reviews and meta-reviews. Of these, 145 duplicated studies were excluded. Upon reviewing the remaining 120 papers, 98 were excluded as they did not align with the criteria. Among these, 28 studies were unrelated to cancer, 42 focused on interventions, 11 did not involve patients, and 17 were not qualitative studies. Ultimately, 22 systematic reviews were considered eligible (Figure 5). Subsequently, from the 22 systematic reviews, 351 papers were selected.





Funded by the European Union




Figure 5 Flow diagram of the articles' selection process




Figure 6 Frequency of psychosocial (A), risk perception (B), lifestyle (C), and environmental/social (D) factors in cancer survivors (blue bar), patients in palliative care (green bar), and those undergoing treatment (orange bar).

The bar chart in Figure 6 provides a detailed comparison of the frequency of psychosocial, risk perception, lifestyle, and environmental factors among three distinct patient groups: cancer survivors EUonQoL Pag. 17 | 100





European Union

(represented by blue bars), individuals in end-of-life/palliative care (green bars), and those undergoing ongoing treatment (orange bars).

Among **psychosocial factors** depicted in Figure 6A, stress and distress were the most frequently reported for cancer survivors, with 246 occurrences highlighting the significant impact of stress on this group. Social and family support and interactions follow, with a count of 175, underscoring the importance of a strong support network. Close behind, coping strategies were identified 168 times, indicating the emphasis on adaptive mechanisms in managing the illness. Psychological distress is noted for its impact on cancer survivors, with 52 occurrences. A range of factors, including anxiety, sense of coherence, optimism, body image concerns, sexual life impairment, fear of cancer recurrence, resilience, and spiritual growth, fell within the 25 to 50 occurrence range, demonstrating a spectrum of psychosocial challenges. Other factors such as resilience, depression, benefit-finding, post-traumatic growth, pessimism, well-being at diagnosis, and hope are mentioned less frequently, each accounting for less than 25 occurrences.

For individuals in the end-of-life patient group, as illustrated by the green bars in Figure 6A, the sense of coherence emerged as the most prominent psychosocial factor, with the highest frequency of 46 occurrences. This reflects the importance of finding meaning and comprehensibility in their experiences at this stage of life. Depression and anxiety were also prevalent concerns, ranking as the second most common factor with 32 occurrences, indicating the psychological challenges that accompany terminal illness. Social and family support and interactions were the third most frequently cited factor (15 occurrences), underscoring the crucial role of supportive relationships in providing comfort and assistance to these patients. While less prominent, other factors such as awareness of terminal disease, intrusive thoughts (10 occurrences), and spirituality/religiosity/spiritual (8 occurrences) well-being were acknowledged, each contributing to the multifaceted psychosocial landscape of end-of-life care.

In the context of ongoing treatment, the bar chart in Figure 6A revealed that the most frequently reported psychosocial factors were stress and distress, with 147 occurrences. This underlines the considerable impact of stress on patients actively receiving treatment. Following stress and distress, coping strategies (88 occurrences) and social/family support and interactions (80 occurrences) stood out as the following most significant factors, indicating the importance of adaptive mechanisms and a reliable support network during treatment. Anxiety ranked as the third most prevalent factor for this group, with 37 occurrences reflecting the commonality of anxiety among patients in active treatment. The incidence of all other psychosocial factors was reported to be below 25 occurrences.

This systematic review evaluated three significant categories of **risk perception factors**: clinical, demographic, and psychosocial. Each category encompasses key aspects illustrated in Figure 6B, which details the frequency of occurrence in each patient group.

Our findings reveal that, among cancer survivors, the affective components of psychosocial factors—such as distress, anxiety, worry, intrusive thoughts, avoidance, and fear of cancer—emerged as the most influential in shaping risk perception, with 165 occurrences. Additionally, within the psychosocial domain, personality traits and coping mechanisms were identified as the second most influential factor in this group, accounting for 105 occurrences. In terms of clinical factors, both personal and familial cancer experiences significantly impacted risk perception among cancer survivors, with 80 instances noted. The cognitive aspect, encompassing beliefs about cancer's preventability, seriousness, and hereditary risks, also affected risk perception, with 33 occurrences in this group. Factors with fewer than 25 occurrences EUonQoL Pag. 18 | 100





European Union

included a psychosocial element related to cultural aspects (22 occurrences), mainly faith and spiritual coping, and clinical factors such as health behaviors (17 occurrences), objective risk assessment (15 occurrences), and other conditions like menopause status (8 occurrences). Demographic factors, including age, race/ethnicity, education, marital status, employment, and gender, also presented less than five occurrences.

Personality traits and coping mechanisms, part of psychosocial factors, were the most frequently identified aspects for patients in palliative care, with 20 occurrences. These include locus of control, monitoring, and punishment/reward sensitivity. Affective responses, another psychosocial component focusing on emotional reactions, were also prevalent, with 17 occurrences. Personal and family cancer experiences, a clinical factor, ranked third in significance for risk perception in end-of-life patients, with 13 instances. Other factors presented few occurrences, such as cultural aspects (6 occurrences), objective risks, and health behaviors, with two occurrences each.

Patients undergoing ongoing treatment exhibited a pattern of risk perception factors similar to that of cancer survivors. The four most prevalent aspects are:

- 1. Affective psychosocial factors, with 101 occurrences
- 2. Personality traits and coping mechanisms, also psychosocial, with 72 occurrences
- 3. Personal and familial cancer experiences, a clinical factor, with 37 occurrences
- 4. Cognitive factors, another psychosocial aspect, with 15 occurrences

Less influential factors in this group included cultural aspects, objective risks (11 occurrences), health behaviors (5 occurrences), and demographic characteristics, accounting for fewer than five occurrences.

The bar chart "Lifestyle factors" in Figure 6C compares the frequency of various **lifestyle factors** among the three patient groups. These factors encompass physical activity, dietary habits, sleep quality, health and routine management, social interactions, substance use, religious and spiritual practices, and intimate life.

For cancer survivors, intimate life emerged as the most significant concern, with 56 recorded occurrences indicating the importance of relationships in this group's QoL. Health management followed with 43 occurrences and daily activities with 33. Other notable factors included dietary factors (31 occurrences), routine adjustment (25 occurrences), physical activity/inactivity and leisure/hobbies with 24 occurrences each, and cultural/religious practices with 18 occurrences. Sleep and energy, reproductive health, and self-care all featured similarly with 12 occurrences. Lifestyle factors with minimal impact, such as complementary and alternative medicine (CAM), smoking/alcohol consumption, and mobility issues, presented fewer than five occurrences.

In the end-of-life/palliative care group, leisure and hobbies appeared most frequently, with eight occurrences underscoring the value of enjoyment and personal interests during this life stage. All the other factors had less prevalence, with fewer than five occurrences.

Health effects were the most significant concern for patients undergoing ongoing treatment, with 19 occurrences. The second most prominent lifestyle factor was physical activity/inactivity, with 17 occurrences. The most relevant factors were leisure and hobbies, routine adjustment, and sex life, with 16 occurrences each. Similarly, health management (15 occurrences), dietary factors (12 occurrences), daily activities (10 occurrences), cultural/religious factors (8 occurrences), and sleep and energy (6 EUonQoL Pag. 19 | 100

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUonQoL	in Europe	Funded by the European Union

occurrences) were also frequent lifestyle factors. The other factors, CAM, self-care, smoking/alcohol, reproductive factors, and mobility, all presented less than five occurrences.

The bar chart "Environmental factors" in Figure 6D offers a comparative analysis of the frequency at which various **environmental and social factors** occur among the three groups of cancer patients. These factors encompass a range of elements, including healthcare provider interactions, information and education, social support, romantic relationships, social isolation, work dynamics, family support, lack of support, healthcare routines, social interactions, cancer group interactions, discrimination, spirituality and religion, sexual encounters, and partner support.

In the case of cancer survivors, interactions with healthcare providers were cited most frequently as the vital factor, with 68 instances underscoring the role played by medical staff in their care. Similarly, information and education were emphasized, with 67 mentions highlighting patients' need to be well-informed about their health and treatment. Social support and work dynamics were also significant factors, with 58 and 44 instances, respectively. Both romantic relationships and lack of support were manifested in 37 occurrences, and social interaction in 30 occurrences. Family dynamics, cancer group interaction, healthcare routine, and societal perception presented 20 to 22 occurrences. The other environmental factors, such as social isolation, sexual encounters, spirituality/religion, discrimination, and partner support, presented 14, 12, 9, 8, and 2 occurrences, respectively.

For end-of-life/palliative care patients, social interactions, family dynamics, and healthcare-provider interactions were the most noteworthy, each with eight instances, followed by information and education, with five occurrences. A diverse array of factors—including social support, work dynamics, lack of support, family support, healthcare routines, societal perceptions, cancer group interactions, social isolation, and spirituality and religion—registered less than five times.

Patients who were undergoing ongoing treatment showed a similar trend to cancer survivors, where interactions with healthcare providers were found to be the main factor in 49 cases. Information and education were the second most significant environmental factor in 25 instances. Family dynamics and social interactions were the third most frequent factor, with 23 occurrences, closely followed by social support, with 22 occurrences. Healthcare routine emerged as the fourth most frequent factor among patients undergoing ongoing treatment, with 20 occurrences. The following environmental factors were observed, and their frequency of occurrence was noted: family support (18), societal perception (16), romantic relationships (13), work dynamics (12), and social isolation (11). On the other hand, factors such as lack of support (9), discrimination (6), spirituality/religion (6), and cancer group interaction (5) were the least frequently occurring factors.




Figure 7 Global and European distribution of studies by country

Figure 7 consists of two **maps** presenting the **distribution of studies** included in the analysis. On the left, a world map titled "Studies per Country" uses varying shades of blue to indicate the number of studies conducted in each country globally. Darker shades of blue represent a higher count of studies, with a legend scaling from light blue (fewer studies) to dark blue (more studies). According to the data, the United States conducted the highest number of studies with 117, followed by Australia with 73, the United Kingdom with 68, Canada with 46, and Sweden with 25 studies. Norway, China, Netherlands, and Denmark had 19, 17, 14, and 12 studies respectively. The remaining countries had less than ten studies, with Brazil having 9, Israel 8, and Ireland, Italy, Korea, Malaysia, New Zealand, Singapore, Taiwan, and Turkey having six studies each. Belgium, Finland, France, Hong Kong, Iran, and Japan had five studies, while Germany, Spain, and Thailand had four. Jordan, Mexico, and Switzerland had three studies, while Cyprus, Greece, India, Nigeria, Palestine, Puerto Rico, South Africa, and Uganda had two. Finally, there was only one study in Barbados, Cameroon, Estonia, Ghana, Indonesia, Pakistan, Romania, Samoa, and Saudi Arabia.

On the right side is a map called "Studies per Country in the European Union," which provides a detailed view of the distribution of studies within Europe. The map uses a color scheme to differentiate the counts, with darker shades indicating more studies. The top five countries in the European Union with the most studies were the United Kingdom (68), Sweden (25), Norway (19), Netherlands (14), and Denmark (12). The other 13 countries had less than ten studies.






Figure 8 Distribution of psychosocial (A), risk perception (B), environmental (C), and lifestyle (D) factors in Western and Eastern European countries.

Figure 8 illustrates the distribution of psychosocial, risk perception, environmental, and lifestyle factors among Western and Eastern European cancer patients. The graph includes three patient groups: cancer survivors (blue bar), those in end-of-life/palliative care (green bar), and those undergoing treatment (orange bar).

Concerning psychosocial factors shown in Figure 8A, the occurrences of various categories were much lower in Eastern Europe than in Western Europe. In Eastern Europe, body image concerns among cancer survivors (3 occurrences) and stress/distress during ongoing treatment (3 occurrences) were the most frequent. On the other hand, Western Europe showed a much higher frequency of factors, particularly coping strategies in cancer survivors (53 occurrences) and stress/distress both in cancer survivors and during ongoing treatment (59 occurrences each). In Western Europe, anxiety, body image concerns, and social/family support were also significantly more frequent compared to Eastern Europe.

EUonQoL

EllonOol	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUONQUL	in Europe	Funded by the European Union

The risk perception factors among cancer patients in Western and Eastern Europe show distinct patterns, as shown in Figure 8B. In Eastern Europe, lower occurrences were noted, with the affective personality and coping categories being the most common among cancer survivors, each with four occurrences. On the other hand, Western Europe reported higher instances across all categories, with personality and coping being the most common among cancer survivors, with 60 occurrences. Other categories, such as cancer experience, cognitive, and affective, also showed notably higher occurrences in Western Europe for both cancer survivors and those in active treatment.

For environmental and social factors in Western and Eastern European countries (Figure 8C), healthcare provider support/interaction for cancer survivors was the most frequent category (45 occurrences), followed by social support for cancer survivors (43 occurrences) and information and education for cancer survivors (30 occurrences). On the other hand, Eastern Europe had much fewer occurrences, with social interaction and social support for cancer survivors being the most noted (4 occurrences each). Furthermore, there were significant differences between the two regions in other categories, such as family support, healthcare routine, work dynamics, and lack of support.

Regarding lifestyle factors, as shown in Figure 8D, Eastern Europe reported minimal occurrences, with only one mention each of cultural/religious factors for cancer survivors, physical activity/inactivity during end-of-life/palliative care, health management, and sleep and energy for cancer survivors. On the other hand, Western Europe showed a higher frequency of various lifestyle factors. The most commonly reported factor was daily activities for cancer survivors, which was mentioned 22 times, followed by sex life for cancer survivors with 20 mentions. Health management and leisure and hobbies, both for cancer survivors, were reported 16 and 14 times, respectively. Physical activity/inactivity for cancer survivors was also notable, with 13 mentions.

4. Sentiment analysis

In recent years, the analysis of social media content has become increasingly relevant in health informatics, offering insights into patient experiences and perceptions (Banaye Yazdipour et al., 2022; Khan et al., 2022; Sugawara et al., 2012).

Cancer, being a critical public health issue worldwide, has been the subject of extensive research in various fields, including psychology, oncology, and patient care. The quality of life for cancer patients is a multifaceted concept, encompassing physical, psychological, and social well-being (Bender et al., 2021). Social media platforms like Twitter have become instrumental in providing a space for patients to share their experiences, concerns, and support networks, thus offering a rich source of data for understanding these aspects (de Ruiter et al., 1993).

The utilization of sentiment analysis in healthcare research has seen significant growth, with studies demonstrating its effectiveness in capturing patient experiences and perceptions from online platforms. This approach enables the extraction of both quantitative and qualitative insights, providing a deeper understanding of the factors impacting the quality of life of cancer patients (Clark et al., 2018). In Italy, where healthcare systems and patient experiences may differ from other regions, it is crucial to

In Italy, where healthcare systems and patient experiences may differ from other regions, it is crucial to analyze and understand the sentiments of cancer patients within this specific context (De Rosis et al.,

EUonQoL





2020). Therefore, this study aimed to identify the overall "mood" behind the text among cancer patients concerning the quality of life expressed in social media posts in Italy. To achieve this objective, one million tweets were collected from Italy, posted between 2014 and 2022, using a Twitter Academic application programming interface. Our focus was to analyze tweets written by individuals who were personally affected by cancer.

4.1. Methodology of NLP process and text analysis

The data collection process for Sentiment Analysis involved the extraction of datasets from the public tweets streaming via the Twitter API. Specifically, the Twarc2 tool was utilized on the PowerShell to extract one million tweets from Italy, spanning the period between May 26, 2014, and December 29, 2022. Further data collection was limited by the loss of access to the Twitter API in February 2023. To prepare the extracted data for analysis, the output file, which was initially in JSON format, was processed and transformed. This was accomplished by flattening the JSON file and converting it into a comma-separated values (CSV) file format. All subsequent analyses on the processed CSV file were performed using Python and R, widely used programming languages for data analysis and visualization. Adopting these steps ensured that the data was cleaned and structured in a way that made it suitable for sentiment analysis, thereby increasing the accuracy and reliability of the results.

In order to preprocess data for sentiment analysis, first a large set of tweets was filtered based on language, selecting those written in Italian (377,048 tweets) and English (289,677 tweets). To further refine the analysis, the SpaCy's regular expressions (regex) were used to filter tweets related to cancer. SpaCy is a powerful tool that is built around NLP (Natural Language Processing) tools. By using the regex functions of SpaCy, it is possible to create better patterns that can take linguistic context into account. For the cancer-related tweets, terms such as "cancer", "cancro", "carcinoma", "tumor", and "neoplasia" were used as filters, resulting in a total of 718 tweets. Those 588 tweets were written in Italian, and 130 were written in English.

To ensure that only tweets written by individuals who were personally affected by this condition were analyzed, the OpenAI's text-davinci-003 model was used to filter tweets written in the first person for cancer. To validate the effectiveness of this approach, a sample of tweets previously classified in the first-person category by OpenAI was also manually inspected. Tweets about personal experiences regarding cancer were also manually identified. This additional step helped ensure that the analyzed tweets were more likely to provide firsthand accounts and perspectives, which can be particularly valuable for sentiment analysis. However, both using OpenAI's model and after the manual validation, no tweet written in the first person or related to personal experiences was identified. Consequently, the sentiment analysis was not concluded.

To better understand the data collected, the tweets were divided into two categories based on the language they were written in - English and Italian. Then, a series of graphical analyses was conducted to gain insights. First, word cloud visualizations were performed for each language to determine the main themes of the tweets. Next, all cancer-related tweets were classified into four groups: Political, Family-Related, News or Research-Related, and Other. The Other category included tweets related to horoscopes, insults to people or things outside of a political context, celebrities or famous people EUonQoL





diagnosed with cancer or dying from it, calls for donations, and marches against cancer, among others. Using this classification, treemap visualizations were created to illustrate the distribution and proportion of each category within the dataset.

4.1.1. Results

Separate Word Cloud plots for Italian and English tweets about cancer were prepared (Figure 9). The two-word cloud plots illustrate the most frequently occurring words in social media discussions about cancer, one for Italian (a) and English (b).

The Italian **word cloud** features "cancro" (cancer in Italian) as the central term, with "prevenzione" (prevention), "ricerca" (research), "pazienti" (patients), and "grazie" (thank you) being prominently displayed. Words like "seno" (breast), "prostata" (prostate), and "tumori" (tumors) indicate the types of cancer being discussed. The term "immunoterapia" (immunotherapy) suggests conversations around specific treatments. Similar to the English word cloud, this one also reflects a blend of medical terms, treatment types, and personal aspects of the cancer experience (Figure 9a).

In the English language **word cloud**, the central and most prominent term is "cancer," surrounded by other significant words such as "breast," "fight," "love," "treatment," and "research." The presence of words like "donate," "support," and "cure" suggests a focus on treatment, recovery, and possibly fundraising or awareness campaigns. The inclusion of "mom," "friend," and "family" indicates personal connections to the disease, hinting at discussions centered on patient experiences and support networks (Figure 9b).




Figure 9 Word cloud plots showing the most frequent words used in Italian (a) and in English (b)

4.1.2. Analysis of Tweet Content

When parsing through the tweets related to cancer, it was noted that most of the tweets containing the words selected for the analysis were either using it in a manner not related to cancer, usually politically charged (e.g. "il cancro della democrazia italiana"), using it to convey news, factoid or research ("Ministero Salute ritira nuovi colori per tatuaggi, rischio cancro!", "Malasanità a Sesto San Giovanni Tribunale di Monza condanna medico per intervento errato per un tumore allo stomaco non esistente.", "Novel

EUonQoL	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	* * * * * * * Funded by the European Union
---------	--	--

Sequencing Approach Seeks to Detect Cancer Genomic Alterations"), or not related to a personal experience, but rather about family or friends that suffer from cancer ("Io Io odio il cancro. Mi sta portando via i nonni, mi ha quasi portato via la mamma e spazza via vite ogni giorno") (Figure 10).

For tweets in Italian, "News or Research" forms the largest category with 283 tweets, illustrating a significant interest in the scientific and informational aspects of cancer within the Italian-speaking community. "Other" includes 253 tweets and encompasses a broad array of topics such as horoscopes, celebrities or well-known figures battling or succumbing to cancer, appeals for charitable contributions, among others. "Politics" is represented with 41 tweets, suggesting a level of discourse on cancer in relation to political issues. "Cancer Related To Family" appears to be the smallest category with 8 tweets, indicating fewer tweets written in Italian explicitly referencing family connections to cancer (Figure 10a).

For tweets written in English, the largest segment is labeled "Other," with 72 tweets, suggesting a diverse range of discussions outside the specified categories. "News Or Research" is represented with 35 tweets, indicating a substantial engagement with content on cancer research and news updates. "Cancer Related to Family" contains 14 tweets, which could reflect stories related to family members' experiences with cancer. The smallest category, "Politics," with 9 tweets, indicates some discussion on cancer within a political context (Figure 10b).

b)



Figure 10 Distribution of tweets related to cancer in Italian (a) and in English (b)

4.1.3. Challenges in Data Collection

EUonQoL

a)

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUonQoL	in Europe	Funded by the European Union

The primary challenge faced was the sheer volume of tweets in comparison to the size of our sample. Considering the global production of approximately 6,000 tweets per second, our dataset might have been too small to capture a representative sample of Italian tweets about cancer. Initially, a modest sample was selected to assess the feasibility of the study, with plans to gather more data subsequently. However, access to the Twitter's API was discontinued in February 2023, which posed a significant limitation.

To expand the dataset, the possibility of gathering data from other popular social media platforms was explored, such as Facebook, Instagram, and Reddit. However, this endeavor was met with limited success. Facebook and Instagram, both part of the Meta platform, have stringent restrictions on accessing public content. According to the documentation provided by Facebook for developers (https://developers.facebook.com/docs/features-reference/page-public-content-access), public content access is limited. In fact, to fetch such data, one would need to be an app developer engaged in providing services such as competitive benchmark analysis.

Reddit, on the other hand, offers an API that allows for the extraction of all public posts and comments from any public subreddit. Nevertheless, the platform is primarily structured around English as the main language of communication. This presents a challenge for this study, which is focused on Italian-speaking users. While there are subreddits dedicated to discussions about cancer, such as r/cancer and r/cancerfamilysupport, they are predominantly populated by English-speaking users from around the globe. This language barrier significantly hinders the ability to analyze sentiment among Italian speakers and underscores the necessity for a more nuanced approach to data collection in future research endeavors.

To minimize these limitations in future research, an exploration of alternative data sources such as forums, blogs, and news websites popular among Italian speakers can provide a more comprehensive view of public sentiment. These sources often have less restrictive data access policies compared to major social media platforms.

5. Conclusions

The aim of the present report is to identify and summarize a range of clinical, cultural, sociodemographic, and psychosocial factors associated with QoL. Obtained results will contribute to highlighting factors affecting QoL among adult cancer patients in different phases of the cancer pathway. The results will also allow for the identification of differences between contributions from WP3 and WP4 aimed to identify domains covered by the EUonQoL-Kit. Additionally, the aforementioned domains, will serve as the basis for determining factors to be included in the CRF developed as part of the WP7 Pilot Survey. Indeed, the overlapping themes between domains of QoL identified by WP4 and factors associated with QoL in 3 URs are the following:

Physical domain (i.e. symptoms, impact of treatment, body image)

Social health (i.e. self-efficacy, ability to cope)

Psychological well-being (i.e. anxiety, depression, sadness, psychological distress, stress, fear of recurrence, spirituality, meaning)

Overall health (overall QoL)

EUonQoL





European Union

Findings retrieved from the 3 URs show that in all cancer groups **anxiety and depression** were the main **psychological factors** negatively affecting QoL in cancer patients in treatment, survivors and patients in palliative care, while **social support** is the main social factor positively affecting QoL. Also, **coping/coping strategy** was another prominent factor positively impacting QoL in active treatment group and in survivors.

For qualitative studies, psychosocial factors like stress and distress, coping strategies, and family support were the most prevalent across cancer survivors and those undergoing treatment. For palliative care patients, a sense of coherence, depression, and anxiety were the most relevant factors. Other important factors, from the risk perception category, such as affective responses, personality traits, coping mechanisms, and personal or family cancer experiences, were significant across all patient groups. Lifestyle factors, such as physical activity, dietary habits, health management, and intimate life, varied across the patient groups. For instance, intimate life was a major concern for cancer survivors, while leisure and hobbies were highlighted in the palliative care group. Environmental and social factors like interactions with healthcare providers, information and education, social support, and work dynamics were key, with cancer survivors emphasizing the importance of healthcare provider interactions and information.

Regarding the use of social media to analyze Italian cancer patients' sentiments, the extraction of insights about these patients' quality of life posed some challenges, mainly due to the loss of Twitter API access and limitations in content access from platforms like Facebook, Instagram, and Reddit. The study results revealed that Italian-language tweets mostly referred to news and research when mentioning cancer, showing less focus on political and family matters compared to the more topic-diverse English-language tweets. The findings point out the cultural and linguistic differences in online cancer-related discussions and the study's shortcomings in accurately representing Italian-speaking cancer patients' experiences. It suggests future research should aim for broader data collection and improved methods to more effectively understand and support cancer patients' needs.

One of the final aims of the present report was to define a set of factors that could be used in the CRF, for all three population groups of patients, during the Pilot phase of the EUonQoL Project.

The identified factors included in the CRF for the 3 population groups, extrapolated from key individual, clinical, psychosocial, and cultural factors identified by WP5 are the following:

Sociodemographic data, including country of birth, place of residence, living situation, total number of members in your household, number of children in your household aged under 18, keeping up with household bills in the last year, and "Do you identify as a person with disability or other chronic condition?". Furthermore, there is a specific theme for both the active treatment group of patients and end-of-life/palliative care patients (support needed to interpret items) and some themes specific for the survivors' group of patients (ECOG performance status, comorbidities, currently undergoing pharmacological treatment for physical symptoms other than pain, involuntary weight loss in the last 6 months, follow-up frequency, support needed to interpret items).





Funded by the European Union

6. Appendix 6.1.List of search strings

6.1.1. Search strings for Scopus

Active Treatment:

(INDEXTERMS (neoplasms) OR TITLE-ABS-KEY (cancer*) OR TITLE-ABS-KEY (tumor*) OR TITLE-ABS-KEY (tumour*) OR TITLE-ABS-KEY (malignanc*) OR TITLE-ABS-KEY (neoplasm*) OR TITLE-ABS-KEY (carcinoma*) OR TITLE-ABS-KEY (oncolog*))

AND (INDEXTERMS ("Quality of Life") OR TITLE-ABS-KEY ("Quality of life") OR TITLE-ABS-KEY ("Health Related Quality Of Life") OR TITLE-ABS-KEY (hrqol) OR TITLE-ABS-KEY (qol))

AND (TITLE-ABS-KEY (factor*) OR TITLE-ABS-KEY (indicator*) OR TITLE-ABS-KEY (characteristic*) OR TITLE-ABS-KEY (predictor*) OR TITLE-ABS-KEY (determinant*))

AND (INDEXTERMS (psychology) OR TITLE-ABS-KEY (psycho*) OR TITLE-ABS-KEY (social) OR TITLE-ABS-KEY (individual) OR TITLE-ABS-KEY (personal) OR TITLE-ABS-KEY ("Psychological Side Effect") OR TITLE-ABS-KEY ("Psychological Factor") OR TITLE-ABS-KEY ("Factor, Psychological") OR TITLE-ABS-KEY ("Psychological Factors") OR TITLE-ABS-KEY (effect) OR TITLE-ABS-KEY (effect) OR TITLE-ABS-KEY (effect) OR TITLE-ABS-KEY (individual) OR

AND ((KEY({systematic review}) OR TITLE({systematic review}))



AND DOCTYPE ("Re")) AND LANGUAGE (english)

AND PUBYEAR > 2012

AND PUBYEAR < 2023

Survivor:

(INDEXTERMS(Neoplasms) OR TITLE-ABS-KEY(cancer*) OR TITLE-ABS-KEY(tumor*) OR TITLE-ABS-KEY(tumour*) OR TITLE-ABS-KEY(malignanc*) OR TITLE-ABS-KEY(neoplasm*) OR TITLE-ABS-KEY(carcinoma*) OR TITLE-ABS-KEY(Oncolog*))

AND (INDEXTERMS("Quality of Life") OR TITLE-ABS-KEY("Quality of life") OR TITLE-ABS-KEY("Health Related Quality Of Life") OR TITLE-ABS-KEY(HRQOL) OR TITLE-ABS-KEY(QOL))

AND (TITLE-ABS-KEY(Factor*) OR TITLE-ABS-KEY(indicator*) OR TITLE-ABS-KEY(Characteristic*) OR TITLE-ABS-KEY(predictor*) OR TITLE-ABS-KEY(determinant*)

AND (INDEXTERMS(Psychology) OR TITLE-ABS-KEY(psycho*) OR TITLE-ABS-KEY(social) OR TITLE-ABS-KEY(individual) OR TITLE-ABS-KEY(personal) OR TITLE-ABS-KEY("Psychological Side Effect") OR TITLE-ABS-KEY("Psychosocial Factor") OR TITLE-ABS-KEY("Factor, Psychosocial") OR TITLE-ABS-KEY("Psychological Factors") OR TITLE-ABS-KEY("Factor, Psychological") OR TITLE-ABS-KEY(affect) OR TITLE-ABS-KEY(effect) OR TITLE-ABS-KEY(related) OR TITLE-ABS-KEY(impact) OR TITLE-ABS-KEY("side effect"))

AND (INDEXTERMS("Cancer Survivor") OR INDEXTERMS(Survivors) OR TITLE-ABS-KEY("Cancer Survivor") OR TITLE-ABS-KEY("Survivors, Cancer") OR TITLE-ABS-KEY("Cancer Survivor") OR TITLE-ABS-KEY("Survivor") OR TITLE-ABS-KEY("Survi



AND ((KEY({systematic review}) OR TITLE({systematic review})) AND DOCTYPE("Re"))

AND LANGUAGE(english)

End of life and Palliative Care:

(INDEXTERMS(Neoplasms) OR TITLE-ABS-KEY(cancer*) OR TITLE-ABS-KEY(tumor*) OR TITLE-ABS-KEY(tumour*) OR TITLE-ABS-KEY(malignanc*) OR TITLE-ABS-KEY(neoplasm*) OR TITLE-ABS-KEY(carcinoma*) OR TITLE-ABS-KEY(Oncolog*))

AND (INDEXTERMS("Quality of Life") OR TITLE-ABS-KEY("Quality of life") OR TITLE-ABS-KEY("Health Related Quality Of Life") OR TITLE-ABS-KEY(HRQOL) OR TITLE-ABS-KEY(QOL))

AND (TITLE-ABS-KEY(Factor*) OR TITLE-ABS-KEY(indicator*) OR TITLE-ABS-KEY(Characteristic*) OR TITLE-ABS-KEY(predictor*) OR TITLE-ABS-KEY(determinant*))

AND (INDEXTERMS(Psychology) OR TITLE-ABS-KEY(psycho*) OR TITLE-ABS-KEY(social) OR TITLE-ABS-KEY(individual) OR TITLE-ABS-KEY(personal) OR TITLE-ABS-KEY("Psychological Side Effect") OR TITLE-ABS-KEY("Psychosocial Factor") OR TITLE-ABS-KEY("Factor, Psychosocial") OR TITLE-ABS-KEY("Psychological Factors") OR TITLE-ABS-KEY("Factor, Psychological") OR TITLE-ABS-KEY(affect) OR TITLE-ABS-KEY(effect) OR TITLE-ABS-KEY(related) OR TITLE-ABS-KEY("individual) OR TITLE-ABS-KEY("side effect"))

AND (INDEXTERMS("Terminal Care") OR INDEXTERMS("Hospice Care") OR INDEXTERMS("Palliative Care") OR TITLE-ABS-KEY("Care, Palliative") OR TITLE-ABS-KEY("Palliative Treatment") OR TITLE-ABS-KEY("Therapy, Palliative") OR TITLE-ABS-KEY("Palliative Therapy") OR TITLE-ABS-KEY("Palliative Care") OR TITLE-ABS-KEY("Palliative") OR TITLE-ABS-KEY("Care, Palliative") OR TITLE-ABS-KEY("Care, Terminal") OR TITLE-ABS-KEY("End of Life Care") OR TITLE-ABS-KEY("Care, End-Of-Life") OR TITLE-ABS-KEY("end of life") OR TITLE-ABS-KEY(palliative) OR TITLE-ABS-KEY(hospice))



AND ((KEY({systematic review}) OR TITLE({systematic review})) AND DOCTYPE("Re"))

AND LANGUAGE(english)

6.1.2. Search strings for Embase

Active Treatment:

('neoplasm'/exp OR cancer*:ti,ab,kw OR tumor*:ti,ab,kw OR tumour*:ti,ab,kw OR malignanc*:ti,ab,kw OR neoplasm*:ti,ab,kw OR carcinoma*:ti,ab,kw OR Oncolog*:ti,ab,kw)

AND ('quality of life'/exp OR 'Quality of life':ti,ab,kw OR 'Health-Related Quality Of Life':ti,ab,kw OR 'Health Related Quality Of Life':ti,ab,kw OR 'And Content of Content of

AND (factor*:ti,ab,kw OR indicator*:ti,ab,kw OR characteristic*:ti,ab,kw OR predictor*:ti,ab,kw OR determinant*:ti,ab,kw)

AND ('psychology'/exp OR psycho*:ti,ab,kw OR social:ti,ab,kw OR individual:ti,ab,kw OR personal:ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Factors':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological':ti,ab,kw OR 'Psycholo

AND ('neoplasm'/exp/dm_dt,dm_rt,dm_su,dm_th OR treatment:ti,ab,kw OR "active treatment":ti,ab,kw OR chemotherapy:ti,ab,kw OR radiotherapy:ti,ab,kw OR endocrine:ti,ab,kw OR adjuvant:ti,ab,kw OR therapy:ti,ab,kw OR therapeutic:ti,ab,kw OR ("neo-adjuvant":ti,ab,kw OR neoadjuvant:ti,ab,kw OR "neo adjuvant":ti,ab,kw OR "n

AND ("systematic review":pt OR 'systematic review'/mj OR 'systematic review':ti,ab,kw) NOT ('animal'/exp NOT 'human'/exp) AND (2013:py OR 2014:py OR 2015:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py)



Survivor:

('neoplasm'/exp OR cancer*:ti,ab,kw OR tumor*:ti,ab,kw OR tumour*:ti,ab,kw OR malignanc*:ti,ab,kw OR neoplasm*:ti,ab,kw OR carcinoma*:ti,ab,kw OR Oncolog*:ti,ab,kw)

AND ('quality of life'/exp OR 'Quality of life':ti,ab,kw OR 'Health-Related Quality Of Life':ti,ab,kw OR 'Health Related Quality Of Life':ti,ab,kw OR 'QOL:ti,ab,kw OR 'Life quality':ti,ab,kw)

AND (factor*:ti,ab,kw OR indicator*:ti,ab,kw OR characteristic*:ti,ab,kw OR predictor*:ti,ab,kw OR determinant*:ti,ab,kw)

AND ('psychology'/exp OR psycho*:ti,ab,kw OR social:ti,ab,kw OR individual:ti,ab,kw OR personal:ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Factors':ti,ab,kw OR 'Psychological Factors':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological Factor':ti,ab,kw OR 'Psychological':ti,ab,kw OR '

AND ('cancer survivor'/exp OR 'survivor'/exp OR "Cancer Survivor":ti,ab,kw OR "Survivors, Cancer":ti,ab,kw OR "Cancer Survivorship":ti,ab,kw OR "Survivorship, Cancer":ti,ab,kw OR "Long-Term Cancer Survivors":ti,ab,kw OR "Cancer Survivor, Long-Term":ti,ab,kw OR "Long Term Cancer Survivors":ti,ab,kw OR "Long-Term Survivors":ti,ab,kw OR "Long Term Survivors":ti,ab,kw OR "Long-Term Survivors":ti,ab,kw OR "Survivors":ti,ab,kw OR "Long-Term":ti,ab,kw OR "Survivors":ti,ab,kw OR "Survivors":ti,ab,kw OR "Long-Term Survivors":ti,ab,kw OR "Long-Term Survivors":ti,ab,kw OR "Long-Term":ti,ab,kw OR "Survivors":ti,ab,kw OR "Survivors":ti,ab,kw OR "Long-Term Survivors":ti,ab,kw OR "Survivors":ti,ab,kw OR "Survivors, Long-Term":ti,ab,kw OR survivorship:ti,ab,kw)

AND ("systematic review":pt OR 'systematic review'/mj OR 'systematic review':ti,ab,kw) NOT ('animal'/exp NOT 'human'/exp) AND [2013-2022]/py

End of life and Palliative Care:

('neoplasm'/exp OR cancer*:ti,ab,kw OR tumor*:ti,ab,kw OR tumour*:ti,ab,kw OR malignanc*:ti,ab,kw OR neoplasm*:ti,ab,kw OR carcinoma*:ti,ab,kw OR Oncolog*:ti,ab,kw)



AND ('quality of life'/exp OR 'Quality of life':ti,ab,kw OR 'Health-Related Quality Of Life':ti,ab,kw OR 'Health Related Quality Of Life':ti,ab,kw OR HRQOL:ti,ab,kw OR QOL:ti,ab,kw OR 'Life quality':ti,ab,kw)

AND (factor*:ti,ab,kw OR indicator*:ti,ab,kw OR characteristic*:ti,ab,kw OR predictor*:ti,ab,kw OR determinant*:ti,ab,kw)

AND ('psychology'/exp OR psycho*:ti,ab,kw OR social:ti,ab,kw OR individual:ti,ab,kw OR personal:ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Side Effect':ti,ab,kw OR 'Psychological Factors':ti,ab,kw OR 'Factor, Psychosocial':ti,ab,kw OR 'Factors, Psychosocial':ti,ab,kw OR 'Psychosocial Factor':ti,ab,kw OR 'Psychological':ti,ab,kw OR 'Psycholo

AND ('terminal care'/exp OR 'palliative therapy'/exp OR "Care, Palliative":ti,ab,kw OR "Palliative Treatment*":ti,ab,kw OR "Therapy, Palliative":ti,ab,kw OR "Palliative":ti,ab,kw OR "Palliative":ti,ab,kw OR "Palliative":ti,ab,kw OR "Care, Terminal":ti,ab,kw OR "End of Life Care":ti,ab,kw OR "End-Of-Life Care*":ti,ab,kw OR "Care, End-Of-Life":ti,ab,kw OR "end of life":ti,ab,kw OR palliative:ti,ab,kw OR hospice:ti,ab,kw)

AND ("systematic review":pt OR 'systematic review'/mj OR 'systematic review':ti,ab,kw) NOT ('animal'/exp NOT 'human'/exp) AND [2013-2022]/py

6.1.3. Search strings for PubMed

Active Treatment:

("Neoplasms"[MeSH Terms] OR cancer*[tw] OR tumor*[tw] OR tumour* [tw] OR malignanc*[tw] OR neoplasm*[tw] OR carcinoma*[tw] OR Oncolog*[tw])

AND ("Quality of Life/psychology"[Mesh] OR "Quality of Life"[Mesh] OR "Quality of life"[tw] OR "Health-Related Quality Of Life"[tw] OR "Health Related Quality Of Life"[tw] OR HRQOL[tw] OR QOL[tw])

AND (Factor*[tw] OR indicator*[tw] OR Characteristic*[tw] OR predictor*[tw] OR determinant*[tw])



AND ("psychology" [Subheading] OR "Psychology"[Mesh] OR "Neoplasms/psychology"[Mesh] OR psycho*[tw] OR social[tw] OR individual[tw] OR personal[tw] OR "Psychological Side Effect"[tw] OR "Psychological Side Effects"[tw] OR "Psychosocial Factors"[tw] OR "Factor, Psychosocial"[tw] OR "Factors, Psychosocial"[tw] OR "Psychological Factors"[tw] OR "Psychological Factors"[tw] OR "Factors, Psychological"[tw] OR "Factors, Psychological"[tw] OR "factors, Psychological"[tw] OR "factors"[tw] OR "factors"[t

AND ("Neoplasms/diet therapy"[Mesh] OR "Neoplasms/drug therapy"[Mesh] OR "Neoplasms/radiotherapy"[Mesh] OR "Neoplasms/surgery"[Mesh] OR "Neoplasms/therapy"[Mesh] OR "Neoplasms/pathology"[Mesh] OR treatment[tw] OR "active treatment"[tw] OR chemotherapy[tw] OR radiotherapy[tw] OR endocrine[tw] OR adjuvant[tw] OR therapy[tw] OR therapeutic[tw] OR (neo-adjuvant[tw] OR neoadjuvant[tw] OR neo adjuvant[tw]))

AND (systematic review[pt] OR "systematic review"[tw]) AND (2013/01/01:2022/12/31[Date - Publication] AND "english"[Language] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))

Survivor:

("Neoplasms"[MeSH Terms] OR cancer*[tw] OR tumor*[tw] OR tumour* [tw] OR malignanc*[tw] OR neoplasm*[tw] OR carcinoma*[tw] OR Oncolog*[tw])

AND ("Quality of Life/psychology"[Mesh] OR "Quality of Life"[Mesh] OR "Quality of life"[tw] OR "Health-Related Quality Of Life"[tw] OR "Health Related Quality Of Life"[tw] OR HRQOL[tw] OR QOL[tw])

AND (Factor*[tw] OR indicator*[tw] OR Characteristic*[tw] OR predictor*[tw] OR determinant*[tw])

AND ("psychology" [Subheading] OR "Psychology"[Mesh] OR "Neoplasms/psychology"[Mesh] OR psycho*[tw] OR social[tw] OR individual[tw] OR personal[tw] OR "Psychological Side Effect"[tw] OR "Psychological Side Effects"[tw] OR "Psychosocial Factors"[tw] OR "Factor, Psychosocial"[tw] OR "Factors, Psychosocial"[tw] OR "Psychological Factors"[tw] OR "Psychological Factors"[tw] OR "Factor, Psychological Factors"[tw] OR "Psychological Factors"[tw] OR "Factor, Psychological Factors"[tw] OR "Factor, Psychological Factors"[tw] OR "Factors, Psychological"[tw] OR "factors, Psycholog



AND ("Cancer Survivors"[Mesh] OR "Survivors"[Mesh] OR "Cancer Survivor"[tw] OR "Survivors, Cancer"[tw] OR "Survivors of Childhood Cancer"[tw] OR "Childhood Cancer"[tw] OR "Childhood Cancer"[tw] OR "Cancer Survivors"[tw] OR "Cancer Survivors"[tw] OR "Cancer Survivorship, Cancer"[tw] OR "Long-Term Cancer Survivors"[tw] OR "Cancer Survivor, Long-Term"[tw] OR "Long Term Cancer Survivors"[tw] OR "Survivors"[tw] OR "Survivors"[tw] OR "Survivors"[tw] OR "Long-Term Survivors"[tw] OR "Long-Term"[tw] OR "Long-Term"[tw] OR "Survivors, Long-Term"[tw] OR survivorship[tw])

AND (systematic review[pt] OR "systematic review"[tw]) AND (2013/01/01:2022/12/31[Date - Publication] AND "english"[Language] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))

End of life and Palliative Care:

("Neoplasms"[MeSH Terms] OR cancer*[tw] OR tumor*[tw] OR tumour* [tw] OR malignanc*[tw] OR neoplasm*[tw] OR carcinoma*[tw] OR Oncolog*[tw])

AND ("Quality of Life/psychology"[Mesh] OR "Quality of Life"[Mesh] OR "Quality of life"[tw] OR "Health-Related Quality Of Life"[tw] OR "Health Related Quality Of Life"[tw] OR HRQOL[tw] OR QOL[tw])

AND (Factor*[tw] OR indicator*[tw] OR Characteristic*[tw] OR predictor*[tw] OR determinant*[tw])

AND ("psychology" [Subheading] OR "Psychology"[Mesh] OR psycho*[tw] OR social[tw] OR individual[tw] OR personal[tw] OR "Psychological Side Effect"[tw] OR "Psychological Side Effects"[tw] OR "Psychological Factors"[tw] OR "Factor, Psychosocial"[tw] OR "Factors, Psychosocial"[tw] OR "Psychosocial Factor"[tw] OR "Psychological Factor"[tw] OR "Factor, Psychological"[tw] OR "Psychological"[tw] OR "Factor, Psychological"[tw] OR "Psychological"[tw] OR "Psychological"[tw] OR "Psychological Factor"[tw] OR "Psychological Factor"[tw] OR "Factor, Psychological"[tw] OR "Psychological"[tw] OR "Psychological"

AND ("Terminal Care/psychology"[Mesh] OR "Hospice Care/psychology"[Mesh] OR "Palliative Care/psychology"[Mesh] OR "Care, Palliative"[tw] OR "Palliative Treatment*"[tw] OR "Therapy, Palliative"[tw] OR "Palliative Therapy"[tw] OR "Palliative Supportive Care"[tw] OR "Supportive Care, Palliative"[tw] OR "Care, Hospice"[tw] OR "Care, Terminal"[tw] OR "End of Life Care"[tw] OR "End-Of-Life Care*"[tw] OR "Care, End-Of-Life"[tw] OR "end of life"[tw] OR hospice[tw])



AND (systematic review[pt] OR "systematic review"[tw]) AND (1990/01/01:2022/12/31[Date - Publication] AND "english"[Language] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))

6.1.4. Search strings used for PsycInfo

Active Treatment:

(exp Neoplasms/ OR cancer*.ti,ab,id. OR tumor*.ti,ab,id. OR tumour*.ti,ab,id. OR malignanc*.ti,ab,id. OR neoplasm*.ti,ab,id. OR carcinoma*.ti,ab,id. OR Oncolog*.ti,ab,id.)

AND (exp "Quality of Life"/ OR "Quality of life".ti,ab,id. OR "Health-Related Quality Of Life".ti,ab,id. OR "Health Related Quality Of Life".ti,ab,id. OR UC.ti,ab,id. OR "QOL.ti,ab,id.)

AND (Factor*.ti,ab,id. OR indicator*.ti,ab,id. OR Characteristic*.ti,ab,id. OR predictor*.ti,ab,id. OR determinant*.ti,ab,id.)

AND (exp Psychology/ OR psycho*.ti,ab,id. OR social.ti,ab,id. OR individual.ti,ab,id. OR personal.ti,ab,id. OR "Psychological Side Effect".ti,ab,id. OR "Psychological Side Effects".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Factor, Psychosocial".ti,ab,id. OR "Factors, Psychosocial".ti,ab,id. OR "Psychosocial Factor".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Factor, Psychological".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Factor, Psychological".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological".ti,ab,id. OR "Factor, Psychological".ti,ab,id. OR "Factors, Psychological".ti,ab,id. OR effect.ti,ab,id. OR related.ti,ab,id. OR impact.ti,ab,id. OR "side effect*".ti,ab,id.)

AND (exp "Antineoplastic Drugs"/ OR exp surgery/ OR exp Treatment/ OR exp pathology/ OR treatment.ti,ab,id. OR "active treatment".ti,ab,id. OR chemotherapy.ti,ab,id. OR radiotherapy.ti,ab,id. OR endocrine.ti,ab,id. OR adjuvant.ti,ab,id. OR therapy.ti,ab,id. OR therapeutic.ti,ab,id. OR (neo-adjuvant.ti,ab,id. OR neoadjuvant.ti,ab,id. OR "neo adjuvant".ti,ab,id.))

AND ("systematic review".dt. OR "systematic review".pt. OR "systematic review".ti,ab,id.)



Survivor:

(exp Neoplasms/ OR cancer*.ti,ab,id. OR tumor*.ti,ab,id. OR tumour*.ti,ab,id. OR malignanc*.ti,ab,id. OR neoplasm*.ti,ab,id. OR carcinoma*.ti,ab,id. OR Oncolog*.ti,ab,id.)

AND (exp "Quality of Life"/ OR "Quality of life".ti,ab,id. OR "Health-Related Quality Of Life".ti,ab,id. OR "Health Related Quality Of Life".ti,ab,id. OR UC.ti,ab,id. OR "QOL.ti,ab,id.)

AND (Factor*.ti,ab,id. OR indicator*.ti,ab,id. OR Characteristic*.ti,ab,id. OR predictor*.ti,ab,id. OR determinant*.ti,ab,id.)

AND (exp Psychology/ OR psycho*.ti,ab,id. OR social.ti,ab,id. OR individual.ti,ab,id. OR personal.ti,ab,id. OR "Psychological Side Effect".ti,ab,id. OR "Psychological Side Effect".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological"

AND (exp Survivors/ OR "Cancer Survivor".ti,ab,id. OR "Survivors, Cancer".ti,ab,id. OR "Cancer Survivorship".ti,ab,id. OR "Survivorship, Cancer".ti,ab,id. OR "Long-Term Cancer Survivors".ti,ab,id. OR "Cancer Survivor, Long-Term".ti,ab,id. OR "Long Term Cancer Survivor*".ti,ab,id. OR Survivor.ti,ab,id. OR "Long-Term Survivors".ti,ab,id. OR "Long-Term".ti,ab,id. OR "Survivors".ti,ab,id. OR "Survivors".ti,ab,id. OR "Long-Term".ti,ab,id. OR "Survivors".ti,ab,id. OR "Long-Term".ti,ab,id. OR "Survivors".ti,ab,id. OR "Survivors".ti,ab,id. OR "Long-Term".ti,ab,id. OR "Survivors".ti,ab,id. OR "Surv

AND ("systematic review".dt. OR "systematic review".pt. OR "systematic review".ti,ab,id.)

End of life and Palliative Care:

(exp Neoplasms/ OR cancer*.ti,ab,id. OR tumor*.ti,ab,id. OR tumour*.ti,ab,id. OR malignanc*.ti,ab,id. OR neoplasm*.ti,ab,id. OR carcinoma*.ti,ab,id. OR Oncolog*.ti,ab,id.)



AND (exp "Quality of Life"/ OR "Quality of life".ti,ab,id. OR "Health-Related Quality Of Life".ti,ab,id. OR "Health Related Quality Of Life".ti,ab,id. OR UC.ti,ab,id. OR UC.ti,ab,id.)

AND (Factor*.ti,ab,id. OR indicator*.ti,ab,id. OR Characteristic*.ti,ab,id. OR predictor*.ti,ab,id. OR determinant*.ti,ab,id.)

AND (exp Psychology/ OR psycho*.ti,ab,id. OR social.ti,ab,id. OR individual.ti,ab,id. OR personal.ti,ab,id. OR "Psychological Side Effect".ti,ab,id. OR "Psychological Side Effects".ti,ab,id. OR "Psychosocial Factors".ti,ab,id. OR "Factor, Psychosocial".ti,ab,id. OR "Psychosocial".ti,ab,id. OR "Psychosocial Factor".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological".ti,ab,id. OR "Psychological Factors".ti,ab,id. OR "Psychological".ti,ab,id. OR "Ps

AND (exp "Terminal Cancer"/ OR exp Hospice/ OR exp "Palliative Care"/ OR "Care, Palliative".ti,ab,id. OR "Palliative Treatment*".ti,ab,id. OR "Therapy, Palliative".ti,ab,id. OR "Palliative Therapy".ti,ab,id. OR "Palliative Supportive Care".ti,ab,id. OR "Supportive Care, Palliative".ti,ab,id. OR "Care, Hospice".ti,ab,id. OR "Care, Terminal".ti,ab,id. OR "End of Life Care".ti,ab,id. OR "End-Of-Life Care*".ti,ab,id. OR "Care, End-Of-Life".ti,ab,id. OR "end of life".ti,ab,id. OR palliative.ti,ab,id. OR hospice.ti,ab,id.)

AND ("systematic review".dt. OR "systematic review".pt. OR "systematic review".ti,ab,id.)

6.2.Table Active treatment

6.2.1. Table 2 - Characteristics of the included studies

Year of publication	Study origin	Study design	Objectives/ai m of the research	Studies	included		Particip	ants	Cancer Grou	qr





Funded by the European Union

				Numb er of studie s includ ed	Type of studies included	Years of publish ed include d articles	Country of origin of included studies	Numb er	Socio- demograph ic characterist ics	Cancer type	•
Ho, P. J., et al 2018	Singapore/Nethe rlads	Systematic review	To summarise the evidence on determinants of health-related quality of life (HRQL) in Asian patients with breast cancer.	57	43 cross- sectional studies and 14 longitudin al studies	2005-2017	Korea (n=17), China (n=14), India (n=8), Taiwan (n=6), Malaysia (n=6), Japan (n=5) and Thailand (n=1)	24538	women living in Eastern Asia, South Central Asia and Southeast Asia	Breast cancer	24538





Nierop-van Baal C., et al. 2019	n, Netherlands/ Belgium	Systematic review	identify the associated factors of hope during treatment in cancer patients.	28 cross- sectional, 2 prospectiv e cohort, 2 randomiz ed controllled trial, 1 longitudin	2009- 2019	Asia (n=14), America (n=10), Europe (n=8), Australia (n=1)	6275	> 18 years, undertreat ment	All cancer types bladder breast cancer central nervous system cervical	3821 78 996 269 480
				al					cancer colorectal leukemia lung	429 70 132

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUonQoL	in Europe	Funded by the European Union

Landry, V., et al. 2022	Canada	Systematic review	to identify relevant studies reporting on patients' HrQoL following total or near-total thyroidectomy (TT) or hemithyroidect omy (HT) with regard to postoperative HrQoL providing peer-reviewed information to clinicians that may be integrated into the shared treatment decision- making process with their patients.		16 cross- sectional, 4 cohort studies, 5 mixed methods or qiualitativ es studies	2003- 2022	Asia (n=9), Europe (n= 8), America (n=6), Africa (n=1), Oceania n=1)	54571	NA	DTC (differentia ted thyroid carcinoma) patients	54571
-------------------------	--------	----------------------	---	--	--	---------------	--	-------	----	--	-------

EllonOol	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUUNQUL	in Europe	Funded by the European Union

Zou, H., et al. 2022	China	Systematic review	to analyze current evidence about economic and humanistic impact of Hepatocellular Carcinoma in gretaer China		2 retrospect ive cohort studies, 1 retrospect ive case- control study, 11 cross- sectional, 11 prospectiv e cohort studies, 1 interrupte d time series, 1 case- control study	before April 2021	Asia (27)	20861	>18 years chinese patients	hepatocell ular carcinoma	20861
Baba, M. A., et al. 2021	Morocco	Systematic review	to determine the exact neurocognitive status andQoL in patients with glioblastoma	13	13 cross- sectional observatio nal studies	2009- 2020	Italy (n=9), France (n=2), Egypt (n=1),	617	>18 years Min-max: 19-85	Glioblasto ma	617





Funded by the European Union

			in the mediterranean region and the different predictive factors resposnible for their deterioration			Turkish (n=1)				
El Haidari, R., et al. 2020	France	Systematic review	to identify the factors associated with HRQoL in the countries of the Middle East	28 cross- sectional, 3 case control, 2 longitudin al	2018	Iran (n=15), Turkey (n=9), Saudi Arabia (n=3), Jordan (n=2), Lebanon (n=1), Kuwait (n=1), Bahrain (n=1), Yemen (n=1)	9323	middle east countries Age range: 25-60	Breast cancer	9323

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * *
EUonQoL	in Europe	Funded by the European Union

Rupp, S. K., et al. 2021	Germany	Systematic review	to identify and summarize factor potentially mpacting	59	Clinical trials, registryba sed studies,	1998- 2020	Canada (n=1), China (n=13), France	75733	>18 years	Gastric cancer	75733



			patients'		cohort		(n=1),				
			overall well-		studies,		Germany				
			being		population		(n=4), Iran				
			5 5		-based		(n=2),				
					studies		Israel				
							(n=1),				
							Japan				
							(n=1) ,				
							Korea				
							(n=18),				
							Portugal				
							(n=1),				
							Sweden				
							(n=3),				
							Taiwan				
							(n=1),				
							Turkey				
							(n=1) ,				
							United				
							Kingdom				
							(n=4),Viet				
							nam (n=1)				
Wintraecken, V. M., et	Netherlands	Systematic	to examine the	12	6 cohort	2004-	China	2729	≥18 years	Breast	2729
al. 2022		review	relationship		studies, 6		(n=1),	-		cancer	-
			between		cross-		Germany				
							,				





Funded by the European Union

			personality and QoL in women with non- metastatic breast cancer	sectional studies		(n=1), Italy (n=1), Netherland s (n=1), Serbia (n=1), USA (n=7)				
Sihvola, S., et al. 2021	Finland	systematic review	to explore resilience and its related factors in adult cancer patients	9 cross- sectional, 2 interventio n (RCT)	2014- 2021	Brazil (n=2), China (n=5), Israel (n=3), Turkey (n=1)	1553	≥18 years mean age: 59 years range age: 18-87 941: male; 623: female	colorectal cancer	1553
Razdan, S. N., et al. 2016	New York, USA	Systematic review	(1) identify studies describing health-related quality of life (HRQOL) in patients following BPM (Bilateral Prophylactic	18 Case Series, 4 Prospecti ve Cohort	1995- 2014	Canada (n=3), Netherland s (n=3), Norway (n=1), Sweden (n=8), Turkey (n=1), UK	2046	women	Breast	2046



			Mastectomy) with or without reconstruction ; (2) assess the effect of BPM with or without reconstruction on HRQOL; and (3) identify predictors of HRQOL post- BPM				(n=1), USA (n=5)				
James, C., et al. 2022	London	Systematic review	To 1) Identify the prevalence, severity and progression of Fear of Cancer Recurrence (FCR) and Prostate- Specific Antigen (PSA) anxiety symptoms in	32	18 longitudin al studies, 14 a cross- sectional studies	2003- 2021	Europe (n=13), North America (n=11), Australia (n=6), Asia (n=2)	9953	males	prostate cancer	9953





prostate
cancer
patients.
2) Evaluate
the evidence
for the
association
between
patient,
disease or
treatment
characteristics
and FCR and
PSA anxiety
symptoms.
3) Assess the
relationship
between FCR
and PSA
anxiety and
other
psychological
and quality of
life outcomes
and their
impact on
mental
wellbeing.





Funded by the European Union

Rimmer, B., et al. 2022	England	Systematic review	aims to systematically identify quantitative studies assessing health-related quality of life in adult low- grade glioma patients.	29	13 cross- sectional studies, 9 longitudin al studies	2001 - 2021	Netherland s $(n=3)$, USA (n=3), China (n=2), Italy (n=2), India (n=2), Japan (n=2), Japan (n=2), Norway (n=2), Australia (n=1), Finland (n=1), Germany (n=1), South Korea (n=1), Sweden (n=1), Turkey (n=1)	2093	Mean age range 35.8 - 49.5 years. Sex range 24-73% female.	2093





Funded by the European Union

Odeo, S. et al. 2020	Kenya	Systematic	aims to	54	21 cross-	2000 -	N/A	7394	Most	Prostate	7394
		review	determine the		sectional	2020			participants	cancer	
			overall health-		studies,				were from		
			related quality		13				Europe and		
			of life and its		prospectiv				America,		
			associated		e Studies,				one few		
			among		5				studies		
			prostate		prospectiv				involved		
			cancer		e cohort				participants		
			patients.		study, 4				from Asia.		
					prospectiv						
					e studies, 3						
					retrospect						
					ive						
					studies, 2						
					longitudin						
					al						
					prospectiv						
					e studies,						
					1						
					longitudin						
					al,						
					observatio						
					nal study,						
					1						
					multicente						





Funded by the European Union

				r, prospectiv e, non- Interventi onal trial study, 1 Phase III, RCT, 1 prospectiv e longitudin al study, 1 cohort study, 1 longitudin al study						
Kang, D., et al. 2020	Korea	Systematic review	aims to evaluate studies assessing the health-related quality of life of hepatocellular carcinoma	23 cohort studies, 13 cross- sectional studies, 9 interventio n studies	2018	China (n=11), USA (n=10), Taiwan (n=6), France (n=4), UK (n=2),	6988	Mean age 58.9 years.	Hepatocell ular carcinoma	6988



			patients from 2009 to 2018				Japan (n=5), Germany (n=2), Italy (n=2), Singapore (n=2), Hong Kong (n=1)				
Aizpurua-Perez, I., et al. 2020	Spain	Systematic review	aims to identify the biopsychosoci al factors involved in the resilience of women with breast cancer and to integrate evidence on the interventions that can contribute to	39	30 cross- sectional studies, 8 interventio n study, 1 longitudin al study	2011 - 2020	Asia (n = 16), Europe (n = 14), America (n = 8), Oceania (n = 1)	6189	Age range 18 - 90 years.	Breast cancer	6189





Funded by the European Union

			significantly enhancing it.							
Sousa, H., et al. 2019	Portugal	Systematic review	aims to present a broader perspective of factors affecting quality of life after breast reconstruction in women with breast cancer.	31 retrospect ive cross- sectional studies , 12 prospectiv e studies, 1 ambispect ive study	2000 - 2018	USA (n=8), UK (n=5), Canada & USA (n=4), The Netherland s (n=3), Sweden (n=3), Canada (n=2), Korea (n=2), Ireland (n=2), Germany (n=2), Spain (n=2), France (n=2), France (n=2), Australia (n=2), Turkey	16683	Mean age 50.9 years.	Breast cancer	16683



							(n=1), Poland (n=1), Norway (n=1), Italy (n=1), Denmark (n=1), Czech Republic (n=1), Brazil (n=1)				
Brandão, T., et al. 2017	Portugal	Systematic review	aims to analyze longitudinal studies that examine factors predicting psychological adjustment of women with breast cancer.	41	41 longitudin al studies	2000 - 2015	USA (n = 10), the Netherland s (n = 8), Australia (n=1), Canada(n =1), Denmark (n=1), France (n=1), Greece	9361 Samp le size range 50- 763	Mean age 53.7 years.	Breast cancer	9361, 00

EUonQoL	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	* * * * * * * Funded by the European Union
---------	--	--

							$\begin{array}{c} (n=1),\\ Hong\\ Kong\\ (n=3), Iran\\ (n=2),\\ Japan\\ (n=1),\\ Norway\\ (n=1),\\ Portugal\\ (n=2),\\ Spain\\ (n=2),\\ South\\ Korea\\ (n=1),\\ Sweden\\ (n=2),\\ Taiwan\\ (n=2),\\ Taiwan\\ (n=2), \end{array}$				
							(n=2), Taiwan (n=2), United Kingdom (n=2)				
Bai, M., et al. 2015	USA	Systematic review	aims to examine the literature for associations	36	32 cross- sectional studies, 4	1996 - 2014	USA (n=27), Jordan (n=2),	18948	N/A	All cancer types (8 studies targeted	18948



between spiritual well- being and quality of life among adults diagnosed with cancer.	longitudin al studies	Australia (n=2), The Netherland s (n=1), Canada(n=1), Iran (n=1), Italy (n=1), Japan (n=1)	breast cancer, prostate or colorectal)
		TOTA L 275.8 55	

6.2.2. Table 3 - Characteristics of the included studies

Year of publication	Factors			Association with QoL	Outcomes
	Psychological factors	Social factors	Clinical factors		
Ho, P. J., et al 2018			comorbidities with other diseases (e.g. hypertension, arthritis, diabetes)	Negative association ->HRQL	Comobridities is associated with lower HRQL
			Tumour characteristics/stage	Negative association ->HRQL	Advanced stage disease is associated with lower HRQL
			chemotherapy	Negative association -> HRQL	chemotherapy is associated with lower HRQL





	lower social support			Negative association -> HRQL	lower social support is associated with lower HRQL
	unmet needs			Negative association -> HRQL NB: vedi sotto one study reported positive associaton - > QoL, one study reported negative association -> QoL	
			Time since diagnosis	Positive association - > HRQL	time since diagnosis is associated with better HRQL
		healthier behaviour		Positive association - > HRQL	Healthier behaviour is associated with better HRQL
			type of surgery	one study reported positive association - > QoL, two studies reported negative association -> QoL	is associated with better QoL, two studies reported type of surgery is
·			radiotherapy	two studies reported positive association - > QoL, one study reported negative assoiation -> QoL	
			hormone therapy	two studies reported positive association - > QoL, one study reported one	





Funded by the European Union

				negative association -> QoL	therapy is associated with lower QoL
	unmet needs			NB: one study reported positive associaton -> QoL, one study reported negative association -> QoL	one study reported unmet needs are associated with better QoL, one study reported unmet needs are associated with lower QoL
		Religion		Positive association - > HRQL	Presence of religion is associated with better HRQOL
			presence of recurrence	Negative association -> HRQL	presence of recurrence is associated with lower HRQOL
			chemotherapy	Negative association -> HRQL	Presence of chemotherapy is associated with lower HRQOL
			Immune therapy	Positive association - > HRQL	Immune therapy is associated with better QoL
-		exercise		Positive association - > HRQL	Presence of exercise is associated with better HRQOL
	distress			Negative association ->HRQL	Symptom of distress is associated with poorer HRQOL
	Optimism			Positive association - > HRQL	optimism is associated with better HRQOL
-	Positive mood			Positive association - > HRQL	Positive mood is associated with better HRQOL
	boredom			Negative association ->HRQL	higher levels of boredom are associated with poorer HRQOL





	in the second se		a laternal large of an ()
	internal locus of control	positive association	
		> QoL	associated with better QoL
	external locus of control	negative associat	on external lous of control is associated
		-> QoL	with ower QoL
	coping mode	Positive associatio	
	coping mode		1 0
		> HRQL	associated with better HRQOL
	empowerment	Positive associatio	
		> HRQL	associated with better HRQOL
	family harmony status	Positive associatio	n - good family harmony status is
	, ,	> HRQL	ssociated with better HRQOL
Nierop-van	hope	positive associatio	n - hope is associated with better QoL
Baalen, C.,		> QoL	
et al. 2019			
Landry, V., et	mental health	negative associat	on Mental health is associated with
al. 2022		-> QoL	lower QoL.
a. 2022	mantal fations		
	mental fatigue	negative associat	
		-> QoL	lower QoL.





	reduced motivation			negative association -> QoL	Reduced motivation is associated with lower QoL.
	distress			negative association -> QoL	Distress is associated with lower QoL.
	anxiety			negative association -> QoL	Anxiety is associated with lower QoL.
	depression			negative association -> QoL	Depression is associated with lower QoL.
	somatization			negative association -> QoL	Somatization is associated with lower QoL.
		Social functioning and interactions		negative association -> QoL	social functioning is associated with lower QoL.
		Role limitations		negative association -> QoL	Rrole limitations are associated with lower QoL.
Zou, H., et al. 2022			better liver functions (lower serum bilirubin levels, higher albumin levels, lower alkaline phosphate levels, better albumine to ALP ratios)	•	better liver functions are asociated with better QoL
			tumor stages	negative associated - > QoL	tumor stages are associated with lower QoL
			inflammatory states	negative associated - > QoL	inflammatory states areassociated with lower QoL
			symptoms (pain, appetite loss)	negative associated - > QoL	severe symptms are associated with lower QoL





	depression			negative associated - > QoL	depression is associated with lower QoL
	resilience			positive association - > QoL	psychological resilience is associated with better QoL
	positive illness perception			positive association - > QoL	positive illness perception is associated with better QoL
	coping			negative associated - > QoL	more emotion-oriented coping is associated with lowerQoL
Baba, M. A., et al. 2021	coping strategies (problem solving and positive thinking)			positive association - > QoL	coping strategies (problem solving and positive thinking) are associated with better QoL
		social support		negative association -> QoL	socal support is associated with lower QoL scores
	avoidance			positive association - > QoL	avoidance is associated with higher QoL score
	anxiety			negative association -> QoL	anxiety is associated with lower QoL
	depression			negative association -> QoL	depression is associated with lower QoL
El Haidari, R., et al.			cancer stage	negative association -> QoL	
2020			presence of metastasis	negative association -> QoL	presence of metastasis is associated with lower QoL
			time since diagnosis	negative association -> QoL	Time since diagnosis is associated with lower QoL





Funded by the European Union

time s	since operation	negative association -> QoL	Time since operation is associated with lower QoL
diseas	se duration	negative association -> QoL	Diseaase duration is associated with lower QoL
meno	pausal status	negative association -> QoL	mazzocco
highe	r symptoms score	negative association -> QoL	Higher symptoms score are associated with lower QoL
pain		negative association -> QoL	Pain is associated with lower QoL
fatigu	е	negative association -> QoL	Fatigue is associated with lower QoL
chem	otherapy	negative association -> QoL	Chemotherapy is associated with lower QoL
hormo	one therapy	positive association - > QoL	Hormone therapy is associated with better QoL
early	treatment	positive association - > QoL	Early treatment is associated with better QoL
breas	t reconstruction surgery	positive association - > QoL	Breast reconstruction surgery is ssociated with better QoL
radiot	herapy	one study reported positive association - > QoL, one study reported negative association -> QoL	one study reported positive association -> QoL, one study reported negative association -> QoL
comp medic	lementary alternative sine	positive association - > QoL	Complementary alternative medicine is associated with better QoL





religiosity		positive association -	Religiosity is associated with bet
		> QoL	QoL
spiritual well-being		positive association -	Spiritual well-being is associat
		> QoL	with better QoL
depression		negative association	Depression is assocated with low
		-> QoL	QoL
anxiety		negative association	Anxiety is associated with low
		-> QoL	QoL
psychological symptoms		negative association	Psychological symptoms
		-> QoL	associated with lower QoL
emotional functioning		negative association	
		-> QoL	with lower QoL
helplessness		negative association	
		-> QoL	lower QoL
coping		negative association	Coping is associated with lower C
		-> QoL	
unmet needs		positive association -	
		> QoL	better QoL
self-efficacy		positive association -	
		> QoL	better QoL
self-regulation		positive association -	Self-regultion is associated w
		> QoL	better QoL
sense of coherence		positive association -	
		> QoL	with better QoL
emotion focus coping		positive association -	Emotion focus coping strategies a
strategies		> QoL	associated with better QoL
	social support	positive association -	Social support is associated w
		> QoL	better QoL





Funded by the European Union

Rupp, S. K., et al. 2021		subtotal gastrectomy	positive association - > QoL	patients underwent to subtotal gastrectomy is associated with better QoL
		total gastrectomy	negative association -> QoL	underwent to total gastrectomy is assolated with lower QoL
	personality type D		negative association -> QoL	Type D personality is associated with lower QoL
	tolerant personality type		positive association - > QoL	Tolerant personaity is associated with better QoL
		nanomedicine	positive association - > QoL	nanomedicine is associated with higher QoL
Wintraecken, V. M., et al.	optimism		positive association - > QoL	optimism is associated with higher QoL
2022	self-efficacy		positive association - > QoL	self-efficacy is associated with higher QoL
	trait anxiety		negative association -> QoL	trait anxiety is associated with lower QoL
	extraversion		positive association - > QoL	extraversion is associated with higher QoL
Sihvola, S., et al. 2021	resilience		positive association - > QoL	resilience is associated with higher QoL





Funded by the European Union

Razdan, S. N., et al.	distress			Negative association -> QoL	Distress is associated with lower QoL After BPM
2016	Body Image (vulnerability)			Negative association -> QoL	Vulnerability is associated with lower QoL After BPM
James, C., et al. 2022	Fear of Cancer Recurrence			Negative association -> QoL	Higher FCR is associated with lower QoL
Rimmer, B., et al. 2022	Coping			Negative association -> QoL	Higher levels of avoidant coping are associated with lower QoL.
	Depression			Negative association -> QoL	Higher level of depression is associated with lower QoL
	Post-traumatic stress disorder			Negative association -> QoL	Post-traumatic stress disorder is associated with lower QoL.
	Post-traumatic growth			Positive association - > QoL	Post-traumatic growth is associated with better QoL.
		Time s diagnnosis/treatment	since	Positive association - > QoL	Clinical: One- and three-years since treatment, is associated with better QoL
		Epilepsy/seizure burden		Negative association -> QoL	Epilepsy/seizure burden is associated with lower QoL
		Tumour grade		Positive association - > QoL	lower tumour grade is associated with better QoL





Funded by the European Union

		Tumour-specific symptoms (e.g. cognitive limitations, seizures)		Tumour-specific symptoms is associated with lower QoL.
		Cancer-specific symptoms(e.g. fatigue, pain)	Negative association -> QoL	cancer-specific symptoms, are associated with lower QoL.
Odeo, S. et al. 2020		neoadjuvant hormonal therapy	Negative association -> QoL	Neoadjuvant hormonal therapy is associated with lower QoL.
		comorbidities	Negative association -> QoL	comorbidities are associated with lower QoL
		higher clinical stage	Negative association -> QoL	higher clinical stage is associated with lower QoL.
		greater cancer severity	Negative association -> QoL	greater cancer severity is associated with lower QoL
		Cancer stage	Positive association - > QoL	Early disease stage (1 & 2) is associated with better QoL.
	Depression		Negative association -> QoL	Depression is associated with lower QoL.
	impaired mental health		Negative association -> QoL	Impaired mental health are associated with lower QoL.
Kang, D., et al. 2020	distress		Negative association -> QoL	Distress is associated with lower QoL.
	sadness		Negative association -> QoL	sadness is associated with lower QoL





Funded by the European Union

	depression			Negative association	depression is associated with lower
				-> QoL	QoL
	illness perception			Positive association -	Illness perception is associated with
				> QoL	higher QoL.
	personal control over the			Positive association -	Personal control over the patients'
	patients' own disease			> QoL	own disease is associated with
					higher QoL.
			transarterial	Negative association	
			chemoembolization	-> QoL	associated with lower QoL.
			hepatic resection	Negative association	hepatic resection is associated with
				-> QoL	lower QoL.
			radio-frequency ablation	Negative association	radio-frequency ablation is
				-> QoL	associated with lower QoL.
			TNM stage	Negative association	Severe TNM stage is associated
				-> QoL	with lower QoL.
			Barcelona Clinic Liver Cancer	5	Barcelona Clinic Liver Cancer tumor
			tumor stage	-> QoL	stage is associated with lower QoL.
		Social function		Negative association	poor social function is associated
				-> QoL	with lower QoL
Aizpurua-	resilience		-	Positive association -	Resilience is associated with higher
Perez, I., et				> QoL	QoL
al. 2020	coping strategies			Positive association -	Appropriate coping strategies is
				> QoL	associated with higher QoL.
	anxiety			Negative association	Anxiety is associated with lower
				-> QoL	QoL.





	depression			Negative association -> QoL	Depression is associated with lower QoL.
		Social support		Positive association - > QoL	Social support is associated with higher QoL.
Sousa, H., et al. 2019	Depression			Negative association -> QoL	Depression is associated with lower QoL
	Harm avoidance			Positive association - > QoL	Higher level of harm avoidanceis associated with higher QoL.
	Neuroticism			Negative association -> QoL	Neuroticism is associated with lower QoL
	Openess			Negative association -> QoL	Openessss is associated with lower QoL
	Satisfaction with esthetic outcome			Positive association - > QoL	Higher level of satisfaction with esthetic outcome are associated with higher QoL.
			Timing of reconstruction	Positive association - > QoL/ No association	Contradictory results are found concerning the association between time after reconstruction and QoL: 1) A study found QoL increased with time after reconstruction; 2) one study found no significant association between them.
			BR-related complications	Negative association -> QoL	BR-related complications are associated with lower QoL





	Fat grafting		Contradictory results are found concerning the association between fat grafting procedures and QoL: 1) A study found no significant associations; 2) one study reported that fat grafting is associated with psychosocial and sexual well-being.
	Chemotherapy	Negative association -> QoL	Chemotherapy is associated with lower QoL
	Body Mass Index (BMI)	Negative association -> QoL	BMI is associated with lower QoL
	Cancer stage	Negative association -> QoL	Cancer stage is associated with lower QoL
Brandão, T., et al. 2017	Chemotherapy	Negative association -> QoL	Chemotherapy is associated with lower QoL
	systematic adjuvant therapy (ie, chemotherapy, tamoxifen, or both)		Systematic adjuvant therapy is associated with lower QoL.
	advanced cancer stage	Negative association -> QoL/no association	Contradictory results are found concerning the association between advanced cancer stage and QoL: 1) three studies found that advanced cancer stage is associated with lower QoL; 2) two studies found no association between them.
	fatigue	Negative association -> QoL	Fatigue is associated with lower QoL.





Funded by the European Union

	Social support	Positive association - > QoL	Social support is associated with higher QoL
Anxiety		Negative association -> QoL	Anxiety is associated with lower QoL
depression		Negative association -> QoL	Depression is associated with lower QoL
psychological well-being		Positive association - > QoL	Psychological well-being is associated with higher QoL
optimism		Positive association - > QoL	Optimism is associated with higher QoL
Neuroticism			
a sense of self-efficacy, confidence about remaining cancer free (addded from Cognitive and perceptual factors "Psychosocial variables were grouped into 6 categories " one of these groups os cognitive and perceptual factors) - added - new			
Coping strategies		Positive association - > QoL	Coping strategies are associated with higher QoL





Funded by the European Union

	body image		Positive association - > QoL / no association	Contradictory results are found concerning the correlation between body image and QoL: 1) 2 studies found that better body image and more satisfaction with appearance is associated with higher QoL; 2) 1 study found no association between body image and QoL.
Bai, M., et al. 2015	Spiritual well-being Faith	-	Positive association - > QoL Positive association - > QoL	Spiritual well-being is associated with higher QoL. Faith is associated with higher QoL.

6.3.Table Survivors

6.3.1. Table 4 - Characteristics of the included studies

	Studies included	Participants	Cancer Group
--	------------------	--------------	--------------

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	<pre>* * * * * * * * Funded by the European Union</pre>
---	---

Author, Year of Publicatio n	Study origin	Study design	Number of studies include d	Type of studies included	Data range of included studies	Country of origin of included studies	Sample size (N)	Socio- demographic characteristics	Cancer type	Cance r stage	Time diagnosis treatment	since or
Zainal et	Malaysia	Systemati	32	20 cross-	1998 - 2012	USA (n=13),	N=10,826	Mean age range	Breast cancer	0-II	1-98 months	
al., 2013		c review		sectional		UK (n=4),	Median	47 - 63.				
				studies, 10		Australia	sample	In the western				
				prospective		(n=2),	size 129.	studies the				
				studies, 1		Netherlands	Sample	ethnic majority				
				case control		(n=2), Turkey	size range	were Caucasians				
				study, 1		(n=2), Norway	15 - 2208.	or white				
				cohort study		(n=1), Japan		(median=80%,				
						(n=1),		range: 30-				
						Germany		100%), three-				
						(n=1), Brazil		quarter of the				
						(n=1), China		subjects were				
						(n=1), , Iran		married				
						(n=1), Taiwan		(median=73%,				
						(n=1), Korea		range=33-				
						(n=1), Italy		100%).				
						(n=1)						

	EUonQo	L	measuring cancer pat	f Life in Oncolo g what matters ients and survi n Europe	for	* * * * * Funded by the European Union					
Howard- Anderson et al., 2012	USA	Systemati c review	i 28	15 cross- sectional studies, 8 longitudinal studies, 5 RCTs	1996 -	2010	N/A	Sample size range 144 - 657.	Women younger than 51 years. Mean age range 33 - 50.	Breast cancer	N/A
Syrowatka et al., 2017	Canada	Systemati c review	i 42	21 cohort studies, 20 cross- sectional studies, 1 retrospectiv e chart review	2001 -	2016	USA $(n=9)$, Taiwan $(n=4)$, China $(n=3)$, Korea $(n=3)$, Sweden $(n=3)$, Italy $(n=2)$, Netherlands (n=2), England $(n=1)$, Germany (n=1), Iran (n=1), Israel (n=1), France (n=1), Scotland $(n=1)$	N=20,216 Sample size range 39 - 2595.	Mean age range 43.6 - 66.4. Age range 24 - 81.	Breast cancer	0–IV

< 2 month - 13,2

years

1-10 years

e EUo	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe Funded by the European Unio									
Rimmer et Engl al., 2022	land System c revier		13 cross- 2 sectional studies, 9 longitudinal studies	2001 - 2021	Netherlands (n=3), USA (n=3), China (n=2), Italy (n=2), India (n=2), Japan (n=2), Norway (n=2), Australia (n=1), Finland (n=1), Germany (n=1), South Korea (n=1), Sweden (n=1), Turkey (n=1)	N=2093. Sample size range 15-260.	Mean age range 35.8 - 49.5. Sex range 24- 73% female.	Low-grade glioma	I-II	1-20 years

	EUonQo	L	measuring cancer pat	f Life in Oncolo g what matters ients and survi n Europe	for	* * * * * * * Funded by the European Union					
Wen et al., 2013	USA	Systemat c review	i 26	10 qualitative studies, 10 quantitative studies, 5 mixed- method approach studies, 1 intervention study	1997 - 2013	N/A	N=7322. Sample size range 9-206.	Mean age range 33 - 75. Age range 29 - 91.	Breast cancer	0–IV	0 - 5 years
Aizpurua- Perez et al., 2020	Spain	Systemat c review	i 39	30 cross- sectional studies, 8 intervention study, 1 longitudinal study	2011 - 2020	Asia (n = 16), Europe (n = 14), America (n = 8), Oceania (n = 1)	Sample size range 10-540.	Age range 18 - 90.	Breast cancer	I–IV	Mean 85 days - 4.9 years
Hamel et al., 2016	Belgium	Systemat c review	i 10	7 cross- sectional studies, 1	2007 - 2015	N/A	N=4246. Sample size range 277 - 1320	The mean age 55.9. 54.9% female.	Melanoma cancer	N/A	Mean 1.2 - 9 years

EUonQoL	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	* * * * * * * Funded by the European Union
---------	--	--

	prospectiv study	e							
Systemati 53 c review	3 36 cro sectional studies, longitudir studies	17	Netherlands (n=9), USA (n=20), Australia (7), Canada (n=3), UK (n=4), Greece (n=2), Germany (n=3), Turkey (n=1), France (n=1), Denmark (n=1), Japan (n=1), China (n=1)	N=36,336 Sample size range 77 - 1966.	Mean age range 61-82.	Colorectal cancer	I–IV	2-12 postdiagnosis	years

• • • E	EUonQoL measur cancer			Life in Oncolo what matters ents and survi Europe	for	* * * * * * * Funded by the European Union								
Dunne et al., 2016	Ireland	Systemati c review	i 24	10 prospective studies, 9 cross- sectional studies	2004 -	2015	UK (1 Norway (n = 2), (n = 2), Australia (n = 2), Netherlan (n = 2), Germany (n = 1), (n = 1), Taiwan (1)	USA the nds China Poland	N=2347. Sample size range 51 - 376.	Age ra 94.	age 61. ange 23– 6 female.	Head and neck cancer	N/A	1 month -7 years

	EUonQo	L	measuring cancer pat	f Life in Oncolo g what matters ients and survi n Europe	s for	* * * * * * * Funded by the European Union					
J. Han et al., 2020	USA	Systemati c review and meta analysis	N	21 cross- sectional studies, 14 longitudinal, prospective studies	2008 -2019	UK (n=9), USA (n=9), Australia (n=8), China (n=3), Canada & Australia (n=2), Taiwan (n=1), Ireland (n=1), Netherlands (n=1), Portugal (n=1),	N=17,215	Mean age 63. Age range 50- 70. The majority of participants (N=24 out of 35 studies) were male, 2 studies included only female participants.	Colorectal cancer		< 11 years after diagnosis
Dahl et al., 2013	Denmark	Systemati c review	57	N/A	1995 - 2012	Scandinavia, Austria, Australia, United States, Syria, Hawaii	N/A	N/A	gynecological cancer	N/A	N/A

	EUonQo	L	measuring cancer pat	f Life in Oncolo g what matter ients and surv n Europe	s for	* * * * * * * Funded by the European Ur					
Koch et al., 2012	Germany	Systema c review		N/A	2002 - 20	10 USA(n=15), Germany (n=1), Norway(n=1), the Netherlands(1))	N=6352 Sample size range 92 - 1366.	Mean age range 44.8 - 75.9. Age range 29- 95. White/Caucasia n or African American in six studies, others had no restriction on race.	head and neck, gynaecological , bladder, prostate, colorectal,	N/A	Mean 1.5 - 21.4 years

	EUonQo	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe					* * * * * * * Funded by th European Ur					
Durosini et al., 2022	Italy	systematic	c 33	23 cross- sectional studies, 1 longitudinal design study, 1 three-wave longitudinal study, 1 longitudinal study, 4 RCTs, 1 experimenta l study, 1 evidence- based intervention s study, 1 ross sectional and longitudinal study	2000 -	2020	N/A	N=6396.	N/A	Breast cancer	N/A	N/A



6.3.2. Table 5 - Characteristics of the included studies

Author,	Study	Study	Fac	tors	
Year of Publication	origin	design	Psychological factors	Social factors	Association with QoL
Zainal et al., 2013	Malaysia	Systematic review	Depression		Depression is associated with lower QoL.
Howard- Anderson et al., 2012	USA	Systematic review	Depression, stress, coping	Social support	Social and emotional support, coping are associated with better QoL. Depressions, stress are associated with lower QoL.
Syrowatka et al., 2017	Canada	Systematic review	Distress		Distress is associated with lower QoL.

	UonQoL		Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe				* * * * * * * Funded by the European Union
Rimmer et al., 2022	England	Systema review	atic	coping, depression, post- traumatic stress disorder, post- traumatic growth			Post-traumatic stress disorder, higher levels of avoidant coping, higher level of depression are associated with lower QoL. Post-traumatic growth is associated with better QoL.
Wen et al., 2013	USA	Systematic review		Emotions, emotional well- being	Social sup	port	Negative emotions are associated with lower HRQoL. Emotional well- being and social support are associated with higher QoL.

• • • E	UonQoL		me	ality of Life in Ond asuring what math cer patients and su in Europe	ters for	* * * * * * * Funded by the European Union				
Aizpurua- Perez et al., 2020	Spain	System		Resilience, coping strategies, anxiety, depression	Social sup	oport Resilience, appropriate coping strategies, social support are associated with higher QoL. Anxiety/depressive symptoms are associated with lower QoL.				
Hamel et al., 2016	Belgium	System review			Social interaction	ns Social interactions are associated with higher QoL.				

EUonQoL	me	ality of Life in Ond asuring what mati cer patients and su in Europe	ters for	* * * * * * Funded by the European Union
	Systematic review	Psychological distress, anxiety, depression, optimism, cancer-threat appraisal, a sense of coherence , repression defense, benefit- finding, posttraumatic growth, faith and meaning/peace, denial, hostility	Social supp	ort Less perceived social support, psychological distress, anxiety, depression, lower optimism and negative cancer-threat appraisal, a weaker sense of coherence, more repression defense, less benefit finding, lower posttraumatic growth, less faith and meaning/peace, and less denial and more hostility are associated with lower HRQoL.

	UonQoL		me	ality of Life in One asuring what mat cer patients and so in Europe	ters for	* * * * * * * Funded by the European Union				
Dunne et al., 2016	Ireland	System		Depression, anxiety, coping, fear of cancer recurrence, body image concerns, emotional and spiritual growth, neuroticism	Social su	pport	Depression, anxiety, avoidance coping, fear of cancer recurrence, body image concerns, neuroticism are associated with lower QoL. Emotional and spiritual growth, perceptions and care received, satisfaction with social support are associated with higher QoL.			

	UonQoL	me	ality of Life in Onc asuring what matt cer patients and su in Europe	ers for	* * * * * * * * * * Funded by the European Union				
J. Han et al., 2020	USA	Syster review meta- analys	v and	Psychological distress, body image distress		Psychological distress, body image distress are associated with lower QoL.			
Dahl et al., 2013	Denmark	analysis Systematic review		Pessimism, fear of cancer recurrence, coping, neuroticism, sense of coherence, hope, well-being at the time of diagnosis, impaired sexual life		Hope, positive coping, high sense of coherence, positive coping, well-being at the time of diagnosis are associated with higher QoL. Pessimism, neuroticism, fear of cancer recurrence, impaired sexual life are associated with lower QoL.			
Koch et al., 2012	Germany	Systematic review		Fear of cancer recurrence		Fear of cancer recurrence is significantly associated with lower QoL			

	UonQoL		me	ality of Life in On asuring what mat cer patients and s in Europe	ters for	* * * * * * * Funded by the European Union
Durosini et al., 2022	Italy			Emotional abilities (EA), coping strategies		Active coping/EA is associated with higher QoL. Passive coping/EA is negatively associated with lower QoL.

6.4. Table End of Life and Palliative Care

6.4.1. Table 6 - Characteristics of the included studies

Author & Year of	Study origin	Study design	Studies included	Participants	Cancer Group
publication	eng	aceigii			



			Number of studies included	Type of studies included	Years of published included articles	Country of origin of included studies	Number of patients in included articles	Range number of patients in included articles	Socio- demogra characte		Cancert	уре	
Gayatri et al. 2021	Indonesia	systematic review	55	36 cross-sectional, 15 cohort studies, 2 RCTs, and 2 quasi- experimental studies.	1999- 2019	Asia (n = 40), Latin America	11380	Range number of included	sex: among studies	varied	all types	cancer	4305
				experimental studies.		and Caribbean		pts: 15-	Age 18-94	range:	blood		25
						region		1245			breast		640
						(n = 10),		1210			cervical	cancer	224
						and Africa					cervix		39
						(n = 5)					colon rectum	and	373
											digestive)	5
											esophag	jeal	105
											esophag	jus	62
											gallblade	der	20
											gastric		123
											gastroin	testinal	228
											genitour tract	inary	24

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * *
EUonQoL	in Europe	Funded by the European Union

					gynecological	315
					head and neck	998
					hepatobilary	114
					larynx	10
					liver	281
					lung	2093
					no number reported	1042
					non small cell lung	10
					oropharynx	22
					ovarian	14
					pancreas	49
					prostate	6
					rectum	13
					respiratory tract	41
					stomach	193
					uterine cervix	6

	Quality of Life in Oncology: measuring what matters for cancer patients and survivors	* * * * * * * * *
EUonQoL	in Europe	Funded by the European Union

Flyum et al. 2021		systematic review and meta- analysys	11	5 prospective/longitudinal, 6 cross-sectional	2009- 2020	Austria (n=1), Canada (n=1), Denmark and Sweden (n=1), Finland (n=3), Netherlands (n=1), Poland (n=2), South Corea (n=1), Turkey (n=1)	839	Range number of included pts: 35-1978	Age range: > 18 sex: varied among studies	colon rectum	and	839	
-------------------------	--	---	----	---	---------------	--	-----	--	---	-----------------	-----	-----	--





Funded by the European Union

Bai et al. 2015	Georgia (USA)	systematic review	36	32 cross-sectional, 4 longitudinal	2014 (n=2), Canada (n=1),	Canada (n=1),	n=2), anada n=1),		number of included	Age range:>'	18	all types	cancer	169011
						Japan (n=1), Jordan (n=2), Iran (n=1), Italy (n=1), Netherlands (n=1), United States (n=27)		pts: 45-8805			breast colorec prostat	ctal	786 258 373	
							182647		sex: among studies	varied				

6.4.2. Table 7 - Characteristics of the included studies

Author &	Factors	Association with QoL	Outcomes
Year of			
publication			





European Union

		Psychological factors	Social factors		
1	Gayatri et al. 2021			Negative association -> QoL	Higher pain intensity is associated with lower QoL
				Negative association -> QoL	Higher symptoms are associated with lower QoL
				Negative association -> QoL	Higher fatigue is associated with lower QoL
			family function/support	Positive association -> QoL	Higher family support is associated with better QoL
		Depression and anxiety		Negative association -> QoL	Higher depression and axiety symptoms are associated with lower QoL
				Positive association -> QoL	Higher symptoms management therapy are associated with better QoL
		spirituality/religiosity		Positive association -> QoL	Spitiuality/religiosity is associated with better QoL
				Positive association -> QoL	Presence of treatments are associated with better QoL
		Diagnosis awareness		one study reported positive association -> QoL; three studies reported a negative association -> QoL	one study reported positive association -> QoL; three studies reported a negative association -> QoL

	* * * * * * * Funded by the European Union
--	--

2	Flyum et al. 2021		Negative association -> HRQoL	more severe disease is associated with lower HRQoL
			Negative association -> HRQoL	effects of radiotherapy are associated with lower HRQoL
		depression	Negative association -> HRQoL	higher levels of depression are associated with lower HRQoL
			Positive association -> HRQoL	higher response to treatment is associated with better HRQoL





Funded by the European Union

		feeling of coherence	Positive association -> HRQoL	higher feeling of coherence is associated with better HRQoL
			Positive association -> HRQoL	better performance status is associated with higher HRQoL
		intrusive thoughts	Negative association -> HRQoL	intrusive thoughts is associated with lower HRQoL
		awareness of terminal disease	Negative association -> HRQoL	awareness of terminal disease is associated with lower HRQoL
3	Bai et al. 2015	Spirituality (Faith and Meaning/Peace)	positive association -> QoL	higher overall spiritual well- being is associated with better QOL





European Union

7. References

- Aromataris, E., Fernandez, R., Godfrey, C. M., Holly, C., Khalil, H., & Tungpunkom, P. (2015). Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. *International Journal of Evidence-Based Healthcare*, *13*(3), 132–140. https://doi.org/10.1097/XEB.000000000000055
- Banaye Yazdipour, A., Niakan Kalhori, S. R., Bostan, H., Masoorian, H., Ataee, E., & Sajjadi, H. (2022).
 Effect of social media interventions on the education and communication among patients with cancer: A systematic review protocol. *BMJ Open*, *12*(11), e066550. https://doi.org/10.1136/bmjopen-2022-066550
- Bender, J. L., Hueniken, K., Eng, L., Brown, M. C., Kassirian, S., Geist, I., Balaratnam, K., Liang, M., Paulo, C. B., Geist, A., Rao, P., Magony, A., Smith, E. C., Xu, W., Liu, G., & Gupta, A. A. (2021). Internet and social media use in cancer patients: Association with distress and perceived benefits and limitations. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 29(9), 5273–5281. https://doi.org/10.1007/s00520-021-06077-0
- Cárceles-Álvarez, A., Ortega-García, J. A., López-Hernández, F. A., Fuster-Soler, J. L., Sanz-Monllor, A., Ramis, R., & Claudio, L. (2020). Environment, lifestyle behavior and health-related quality of life in childhood and adolescent cancer survivors of extracranial malignancies. *Environmental Research*, *189*, 109910. https://doi.org/10.1016/j.envres.2020.109910
- Clark, E. M., James, T., Jones, C. A., Alapati, A., Ukandu, P., Danforth, C. M., & Dodds, P. S. (2018). A Sentiment Analysis of Breast Cancer Treatment Experiences and Healthcare Perceptions Across Twitter (arXiv:1805.09959). arXiv. https://doi.org/10.48550/arXiv.1805.09959
- De Rosis, S., Cerasuolo, D., & Nuti, S. (2020). Using patient-reported measures to drive change in healthcare: The experience of the digital, continuous and systematic PREMs observatory in Italy. BMC Health Services Research, 20(1), 315. https://doi.org/10.1186/s12913-020-05099-4





- de Ruiter, J. H., de Haes, J. C. J. M., & Tempelaar, R. (1993). Cancer patients and their network: The meaning of the social network and social interactions for quality of life. *Supportive Care in Cancer*, *1*(3), 152–155. https://doi.org/10.1007/BF00366062
- Khan, M. I., Rahman, Z. U., Saleh, M. A., & Khan, S. U. Z. (2022). Social Media and Social Support: A
 Framework for Patient Satisfaction in Healthcare. *Informatics*, 9(1), Articolo 1.
 https://doi.org/10.3390/informatics9010022
- Murphy, N., Moreno, V., Hughes, D. J., Vodicka, L., Vodicka, P., Aglago, E. K., Gunter, M. J., & Jenab, M.
 (2019). Lifestyle and dietary environmental factors in colorectal cancer susceptibility. *Molecular Aspects of Medicine*, 69, 2–9. https://doi.org/10.1016/j.mam.2019.06.005
- Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan—A web and mobile app for systematic reviews. *Systematic Reviews*, *5*(1), 210. https://doi.org/10.1186/s13643-016-0384-4
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Systematic Reviews*, *10*(1), 89. https://doi.org/10.1186/s13643-021-01626-4
- Parkin, D. M., Boyd, L., & Walker, L. C. (2011). 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. *British Journal of Cancer*, 105 Suppl 2(Suppl 2), S77-81. https://doi.org/10.1038/bjc.2011.489
- Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., & Henry, D. A. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* (*Clinical Research Ed.*), 358, j4008. https://doi.org/10.1136/bmj.j4008





Spencer, L., Ritchie, J., Lewis, J., & Dillon, L. (2004). *Quality in Qualitative Evaluation: A framework for assessing research evidence*.

- Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., Tierney, J. F., & PRISMA-IPD Development Group. (2015). Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: The PRISMA-IPD Statement. *JAMA*, *313*(16), 1657–1665. https://doi.org/10.1001/jama.2015.3656
- Sugawara, Y., Narimatsu, H., Hozawa, A., Shao, L., Otani, K., & Fukao, A. (2012). Cancer patients on Twitter: A novel patient community on social media. *BMC Research Notes*, *5*(1), 699. https://doi.org/10.1186/1756-0500-5-699
- Tilburt JC, et al. (2012). Factors Influencing Cancer Risk Perception in High Risk Populations: A
 Systematic
 Review.

https://www.google.com/search?q=Tilburt+JC%2C+James+KM%2C+Sinicrope+PS%2C+Eton+D T%2C+Costello+BA%2C+Carey+J%2C+et+al.+Factors+Influencing+Cancer+Risk+Perception+in +High+Risk+Populations%3A+A+Systematic+Review.+Hered+Cancer+Clin+Pract.+2011+May+1 9%3B9(1)%3A2.&rlz=1C1GCEB_enIT1003IT1004&oq=Tilburt+JC%2C+James+KM%2C+Sinicro pe+PS%2C+Eton+DT%2C+Costello+BA%2C+Carey+J%2C+et+al.+Factors+Influencing+Cancer +Risk+Perception+in+High+Risk+Populations%3A+A+Systematic+Review.+Hered+Cancer+Clin +Pract.+2011+May+19%3B9(1)%3A2.&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBBzQ3N2owajeo AgiwAgE&sourceid=chrome&ie=UTF-8

van Roekel, E. H., Bours, M. J. L., de Brouwer, C. P. M., Ten Napel, H., Sanduleanu, S., Beets, G. L., Kant, I. J., & Weijenberg, M. P. (2014). The applicability of the international classification of functioning, disability, and health to study lifestyle and quality of life of colorectal cancer survivors. *Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for*





Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(7), 1394-

1405. https://doi.org/10.1158/1055-9965.EPI-13-1144





Funded by the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.